Introduction {#s1}
============

Muscle Dystrophin establishes a link between Dystroglycan complexes at the cell membrane and actin in the cortical cytoskeleton ([@bib29]; [@bib43]; [@bib23]; [@bib53], [@bib54]). Mutations in the *Dystrophin* gene often lead to a non-functional protein and Duchenne muscular dystrophy (DMD), characterised by severe muscle degeneration from early childhood. In-frame deletions within the Dystrophin sequence can result in a shortened but partially functional protein that causes Becker muscular dystrophy (BMD) ([@bib37]).

A major international effort aims to develop gene therapy for DMD. Yet, there are still big gaps on our understanding of how Dystrophin works within cells. It is important to understand the dynamics of Dystrophin in vivo and how this could vary within cellular context, influencing the phenotype of BMD and gene therapy planning for patients with DMD. For example, many current approaches for gene therapy in DMD aim to restore 'short' Dystrophins, known to be partially functional from studies of patients with BMD and murine transgenic models ([@bib38]). How the dynamics of these proteins compare with those of full-length Dystrophin has not been addressed due to the lack of a suitable method. However, if some short Dystrophin forms bind more efficiently and stably than others this will have an impact on the relative amount of protein necessary to recover function. The knowledge of Dystrophin dynamics and a methodology to perform comparative studies is therefore needed.

Dystrophin is well studied in zebrafish and its homology with the human Dystrophin is well documented ([@bib26]; [@bib30]; [@bib7]; [@bib40]). Several mutant and transgenic lines have been used as model for Duchenne muscular dystrophy and testing potential therapeutic targets ([@bib39]; [@bib31]; [@bib34]; [@bib62]; [@bib67]). The loss of Dystrophin is lethal to both people and zebrafish, primarily due to striated muscle defects ([@bib5]; [@bib6]). Both species show developmental progression towards the adult localisation of Dystrophin. In human embryos, Dystrophin first appears in the cytoplasm, at the tips of myotubes, then becomes widespread throughout the myofibres in foetal stages ([@bib65]; [@bib18]; [@bib16]; [@bib47]; [@bib59]). In embryonic zebrafish muscle, Dystrophin transcripts are reported to accumulate initially in the cytoplasm, and from 24 hr post fertilization (hpf) until early larval stages, Dystrophin protein and transcripts are primarily located at muscle fibre tips ([@bib5]; [@bib26]; [@bib30]; [@bib9]; [@bib52]). In both species, Dystrophin becomes localised under the sarcolemma in maturing and adult muscle fibres where it concentrates at costameres, neuromuscular and myotendinous junctions ([@bib56]; [@bib46]; [@bib15]; [@bib26]). Dystrophin half-life is believed to be very long ([@bib58]; [@bib61]). Therefore, to study Dystrophin binding dynamics, it may be advantageous to look at the moment where binding complexes are actively forming, during muscle development.

Study of protein dynamics in living tissue faces many technical hurdles that no available method can tackle satisfactorily. Fluorescence correlation spectroscopy (FCS) requires stable confocal imaging of submicron volumes and is thus sensitive to drift in living tissue. Moreover, FCS is only applicable over a limited range of fluorophore concentrations and is greatly impeded by the presence of significant quantities of immobile fluorophores. Fluorescence recovery after photobleaching (FRAP) avoids these problems. However, imaging in a living organism is challenging due to low signal-to-noise ratio that worsens as tissue thickness increases and protein abundance decreases. In addition, cells are located at variable optical depths and have varying shapes and protein levels, all of which introduces variability. This hampers identification of real variation in protein dynamics and prevents the common procedure of pooling data from multiple cells to reduce noise.

In this study, we assess human Dystrophin dynamics in muscle cells of host zebrafish embryos, using a new approach to perform and analyse FRAP in the context of the living muscle fibre that specifically deals with the challenges of in vivo protein analysis. We thoroughly characterize the expression of the exogenous human Dystrophin within zebrafish host muscle cells. Overexpression often results in an excess of cytoplasmic Dystrophin, which is taken into account on the analysis of Dystrophin binding dynamics. We demonstrate that Dystrophin diffuses freely in the zebrafish muscle fibre cytoplasm and determine its diffusion constant. At the binding sites localised at the muscle cell tips, we found the existence of two membrane-bound pools with distinct binding constants: an immobile pool bound stably during our imaging timescale and a mobile-bound pool with a highly dynamic turnover. We test several potential factors that could potentially interfere with the binding dynamics of Dystrophin, or with its analysis, and result in wrong identification of a labile-bound pool: lateral diffusion of bound Dystrophin, transient dark state of fluorescent proteins, artificial increase of the cytoplasmic pool, competition with endogenous zebrafish Dystrophin, or weak interaction between inter-species proteins. Our data allowed us to dismiss all these hypotheses, supporting the real existence of two bound forms of Dystrophin in maturing fibres of the zebrafish embryo. Taken together, these results suggest a model for Dystrophin association with the membrane and provide a baseline and a validated methodology to analyse how modifications in Dystrophin structure may alter its dynamics.

Results {#s2}
=======

Dystrophin mRNA and protein localization are environmentally determined {#s2-1}
-----------------------------------------------------------------------

We set out to analyse human Dystrophin protein dynamics in vivo in the physiological environment of the muscle fibres of zebrafish embryos ([Figure 1](#fig1){ref-type="fig"}). We engineered expression constructs based on the full-length 427 kd human cDNA sequence (huDys; [Figure 1A](#fig1){ref-type="fig"}; 'Materials and methods'). Expression of huDys or GFP control in zebrafish embryos was achieved through the injection of the DNA constructs into newly fertilized embryos at the early 1 cell stage, aiming to obtain mosaic expression to facilitate single cell analysis ([Figure 1B,C](#fig1){ref-type="fig"}). From 24 hpf onwards, huDys ([Figure 1C](#fig1){ref-type="fig"}, green) accumulated progressively at both ends of transgenic fibres (hereafter referred to as 'tips'), as observed for endogenous zebrafish Dystrophin ([Figure 1C](#fig1){ref-type="fig"}, red). GFP control showed no tip accumulation ([Figure 1D](#fig1){ref-type="fig"}). In addition, huDys was often detected accumulating at putative neuromuscular junctions (NMJ), like endogenous Dystrophin (arrows in [Figure 1E,F](#fig1){ref-type="fig"}). We conclude that human Dystrophin localises in zebrafish skeletal muscle like zebrafish Dystrophin, making it likely, in a first approach, that the zebrafish embryo could be a suitable host to study human Dystrophin in vivo.10.7554/eLife.06541.003Figure 1.Human Dystrophin expression in the zebrafish embryo.(**A**) Main features of the human Dystrophin expression constructs engineered for this study. (**B**) Schematic illustrating 2 dpf zebrafish embryo. Slow muscle fibres within the chevron-shaped somite, one magnified and highlighted in blue, are typically aligned anterior-posteriorly with their tips (dark blue) attaching at vertical somite borders. (**C**) Immunofluorescent detection of exogenous huDys (green, arrows) at fibre tips, co-localizing with endogenous zebrafish Dystrophin (zfDys, red) that accumulates at the tips of every muscle fibre, marking the somite border. (**D**) In vivo expression of control GFP shows accumulation in muscle fibre cytoplasm without enrichment at the fibre tips. (**E**) Immunodetection with antibody specifically recognizing human Dystrophin on whole mount 2 dpf embryo shows punctate accumulation of exogenous huDys (arrow) suggestive of localization at the NMJ, in addition to fibre tips (arrowheads). (**F**) Immunodetection on longitudinal cryostat sections of 2 dpf somitic muscle shows enrichment of endogenous zebrafish Dystrophin (zfDys) at NMJ (arrows). Note concentration of most zfDys at fibre tips (arrowheads). (**G**) Maximum intensity projection of a confocal stack showing accumulation of huDysGFP in a muscle fibre in vivo. Strong enrichment is noticeable at the tips (arrows), membrane protrusions (yellow arrowheads), and NMJ (red arrowheads). (**H**) Double immunofluorescent detection of GFP in a huDysGFP-expressing embryo (huDysGFP, green) and α-bungarotoxin (BTX, red) confirms co-localization at the NMJ (insert). (**I**, **J**) huDysGFP mRNA detected by in situ hybridization (arrows in **I**, Nomarski) localises at fibre tips like GFP fluorescence detected while in vivo (arrows in **J**; confocal maximum projection). Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.003](10.7554/eLife.06541.003)

To allow the in vivo study of huDys dynamics, the expression construct was modified to produce huDys tagged with GFP at its C-terminus (huDysGFP; [Figure 1A](#fig1){ref-type="fig"}; 'Materials and methods'). This produces a bright fluorescent signal easily detectable at fibre tips ([Figure 1G](#fig1){ref-type="fig"}, arrows). Occasionally, some cells showed accumulations at membrane protrusions ([Figure 1G](#fig1){ref-type="fig"}, yellow arrowheads) and NMJs ([Figure 1G](#fig1){ref-type="fig"}, red arrowhead). The latter was confirmed by double staining with α-bungarotoxin ([Figure 1H](#fig1){ref-type="fig"}, inset). Compared to GFP alone, huDysGFP was generally less bright ([Figure 2A](#fig2){ref-type="fig"}) but was, nevertheless, more readily detected in muscle than non-muscle tissue ([Figure 2B](#fig2){ref-type="fig"}), suggesting that binding and stabilization at the membrane differ between tissues.10.7554/eLife.06541.004Figure 2.Comparison of huDysGFP and GFP expression in 2 dpf zebrafish embryos.(**A**) Total cellular GFP signal (sum of pixel values) of sum projections made from confocal optical sections of individual muscle fibres expressing GFP or huDysGFP in vivo. N~GFP~ = 10 fibres, N~huDysGFP~ = 32 fibres; p \< 0. 0001. (**B**) Fraction of muscle fibres among positive cells in embryos expressing huDysGFP or GFP in vivo. N~GFP~ = 1593 cells in 27 embryos, N~huDysGFP~ = 472 cells in 28 embryos; p = 0. 0032. Error bars show S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.004](10.7554/eLife.06541.004)

To determine whether human *Dystrophin* mRNA becomes localised in zebrafish muscle like the endogenous transcripts, in situ mRNA hybridization with a human *Dystrophin*-specific probe was performed on injected embryos. In most cases, localisation of human *Dystrophin* mRNA was observed at fibre tips ([Figure 1I,J](#fig1){ref-type="fig"}). Thus, GFP-tagged Dystrophin localises similarly to its untagged counterpart, and to the endogenous Dystrophin mRNA and protein, and it is suitable for in vivo imaging.

Increase of cytoplasmic Dystrophin does not affect accumulation at the fibre tips {#s2-2}
---------------------------------------------------------------------------------

Both endogenous Dystrophin and huDysGFP accumulate at the fibre tips, yet the endogenous form is not readily detected in cytoplasm in immunofluorescence assays, that is, it is not clear that the fluorescence detected is higher than background ([Figure 1F](#fig1){ref-type="fig"}), in contrast most fibres expressing huDysGFP show weak but detectable fluorescence in the cytoplasm ([Figure 1G,H](#fig1){ref-type="fig"}). We investigated this difference.

As intensity around 3 units above the background is easily detected under our imaging conditions ('Materials and methods'), we can distinguish huDysGFP in a cytoplasmic voxel (a three dimensional pixel of 0.024 µm^3^) down to a number per voxel around 60 times lower than in the brightest fibre tip voxel (avoiding saturation of the detector by setting it to under 255 on 8-bit grayscale). As less than 1% of the entire cell volume is in the tip region, it is possible that even in cells with cytoplasmic huDysGFP below detectable levels there could be as much huDysGFP in the cytoplasm as in the tip region. This could equally be the case for endogenous Dystrophin. Therefore, the observed difference may be partially due to lower sensitivity of the antibody detection of cytoplasmic endogenous Dystrophin compared to the higher sensitivity of GFP detection. However, higher levels of cytoplasmic accumulation are likely an artefact of the overexpression of exogenous Dystrophin. Therefore, to confidently analyse Dystrophin binding dynamics, the presence of this cytoplasmic pool has to be taken into account and a deeper characterisation is required.

We analysed in more detail how each pool, tips, and cytoplasm, distribute. As predicted, in the majority of the muscle fibres, most huDysGFP is in the cytoplasm, with only a minority at the tips ([Figure 3A](#fig3){ref-type="fig"}), even though the higher concentration at the tips might have suggested otherwise ([Figure 1G,H](#fig1){ref-type="fig"}). Even in cells with cytoplasmic levels close to the detection limit, there is at least as much huDysGFP dispersed in the whole cytoplasm as that concentrated at the tips ([Figure 3A](#fig3){ref-type="fig"}). Across a population of fibres, more huDysGFP fluorescence was detected in the cytoplasm of fibres with higher total huDysGFP levels (blue triangles in [Figure 3A](#fig3){ref-type="fig"}). In contrast, the fluorescence at the tips does not increase with the total fluorescence of the fibre (green circles in [Figure 3A](#fig3){ref-type="fig"}), indicating that tip binding is limited by the presence of a limited number of binding sites that easily saturate. Thus, the accumulation of huDysGFP in the fibre cytoplasm does not appear to affect the binding at the tips. Also, fibre tips generally had greater fluorescence intensity than fibre cytoplasm ([Figure 3B,C](#fig3){ref-type="fig"}). High intensities at the tips can be achieved even with low cytoplasmic huDysGFP concentrations ([Figure 3B](#fig3){ref-type="fig"}). Moreover, at low overall fibre intensities, there is clear preference for accumulation at the tips ([Figure 3C](#fig3){ref-type="fig"}). All these data indicate that human Dystrophin is preferentially bound at the zebrafish fibre tips regardless of the amount of cytoplasmic Dystrophin.10.7554/eLife.06541.005Figure 3.Comparison of tip and cytoplasm huDysGFP.(**A**) Variation of the total fluorescence (as raw integrated density or sum of pixel values) at tips (green circles) and cytoplasm (blue triangles) over a population of 32 fibres expressing huDysGFP. (**B**) Mean voxel intensity at tips versus cytoplasm in sum projection of confocal z-stacks. The mean voxel intensity is calculated as the integrated density per pixel in the sum projections, therefore taking into account the fibre and tip size. (**C**) Ratio tip/cytoplasm voxel intensities shows an inverse correlation with the total fibre voxel intensity in sum projections of confocal z-stacks. p value = 0.0004, *R*^*2*^ = 0.3443, n = 32.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.005](10.7554/eLife.06541.005)

Dystrophin diffuses freely in the cytoplasm {#s2-3}
-------------------------------------------

To study Dystrophin dynamics in our system, we still have to take into account the presence of a cytoplasmic pool. Dystrophin is a high molecular mass protein with multiple actin binding sites. We asked whether huDysGFP can diffuse freely in muscle fibre cytoplasm or whether it may be bound to cytoplasmic structures such as actin fibres.

We developed a modified FRAP approach to analyse protein dynamics in vivo. Even in the best imaging conditions, one faces the challenge of low signal-to-noise ratio that worsens as tissue thickness increases and protein abundance decreases. Although we are able to detect cytoplasmic huDysGFP, the signal is weak and the signal-to-noise ratio in single pixels or even small volumes is low ([Figure 4A](#fig4){ref-type="fig"}). To address these issues, we increase the signal by increasing laser power and studying large areas ('Materials and methods'). Under these conditions, we acquire a consistent signal both for GFP and huDysGFP. However, using a high laser power to image over large areas results in significant photobleaching during imaging, and, even at 100% laser power, bleaching is so slow that significant diffusion occurs during bleaching ([@bib64]). We compensate for both using a mathematical model applied to the FRAP experimental data ('Materials and methods'). This was integrated in a user-friendly application written to allow easy data analysis of multiple experiments (see 'Materials and methods').10.7554/eLife.06541.006Figure 4.Bleaching areas: size optimization, orientation, and definition of Cartesian coordinates.(**A**) Noise reduction in GFP FRAP curve for increasing areas: 1 (blue), 25 (red) and 256 (black) pixels. (**B**) To determine *D* along the *X*-axis (arrowheads) of individual muscle cells in the embryo, two large regions of different widths (narrow and wide; see [Table 1](#tbl1){ref-type="table"}) are bleached sequentially and separated by \>1 min to ensure full recovery. (**C**) *XYZ* view from Volocity of a typical muscle fibre expressing huDysGFP in vivo. The cut planes shown correspond to panels **D**--**F**. (**D**) Muscle fibre imaged in the *XY* plane from a lateral position of the zebrafish embryo as embedded for FRAP. When referring to the fibre tips, we use a different set of axes: the long axis of the tip is the *X*~*T*~ axis and the shorter is the *Y*~*T*~ axis. (**E**, **F**) *YZ* and *XZ* sections, respectively, through the muscle fibre, showing lower *Z* resolution. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.006](10.7554/eLife.06541.006)

To validate our experimental conditions and FRAP analysis method in the muscle cells of zebrafish embryos, we first analysed GFP diffusion within the cytoplasm. We studied diffusion along the long axis of the muscle cell ([Figure 4B](#fig4){ref-type="fig"}). The selected fibre is oriented such that the image *X*-axis aligns to the fibre long axis (i.e., roughly anterior-posterior in the animal) and the *Y*-axis is dorso-ventral ([Figure 4C--F](#fig4){ref-type="fig"}). In each cell, one or two large rectangles of different sizes (narrow and wide) were bleached, avoiding nuclei ([Figure 4B](#fig4){ref-type="fig"}). The bleached rectangles are shorter along the *X*-axis than in *Y* and cross the entire cell transversely. This makes recovery almost entirely due to mobility along the *X*-axis, simplifying modelling and fitting. We analyse the profile along the *X*-axis taken immediately after bleaching GFP-expressing fibres ([Figure 5A](#fig5){ref-type="fig"}). This profile is not a top-hat but a Gaussian, much wider than the region actually bleached, consistent with diffusion during the bleaching phase. This diffusion is taken into account in the modelling as neglecting it would lead to significant error ([@bib13]; [@bib25]; [@bib49]) ('Materials and methods').10.7554/eLife.06541.007Figure 5.Analysis of cytoplasmic diffusion.(**A**--**D**) FRAP experimental data and fitting curves. Normalized intensity profile along the *X*-axis of GFP (**A**) or huDysGFP (**C**) at the first time point after bleaching (blue crosses) and Gaussian fits (red curves). Recovery curves for GFP (**B**) and huDysGFP (**D**) along *X*-axis in which the cyan crosses show normalized fluorescence intensity in the bleached region. Curves are fits of the diffusion model to ∼7 s (red) or ∼40 s (two-parameters, solid black; one-parameter, dashed) post-bleach. (**E**) *D*~GFP~ and *D*~huDysGFP~ obtained from two-parameter fits to ∼40 s of FRAP experimental data (see [Table 1](#tbl1){ref-type="table"}). Graph shows median, quartile, range, and *n*. Comparison was by two tailed *t*-test after test for normality. (**F**) Scatter plot of *D* values obtained for pairs of bleaching experiments performed in the same cell. For huDysGFP (triangles), the two *D* values measured in the same cell, in areas of different widths (narrow/wide), show a good correlation (triangles; Pearson R = 0.98). The triangles are not far from falling on a straight line of slope one. The small cell-to-cell variation in huDysGFP, relative to the variation between cells suggests that the mobility of huDysGFP genuinely varies from one fibre to another. For GFP, there is no definite trend visible, just scatter, presumably due to lower signal-to-noise with the more rapid diffusion of GFP. It is, therefore, not clear whether the mobility of GFP varies significantly from one fibre to another.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.007](10.7554/eLife.06541.007)

We fit the recovery for each individual case to obtain the diffusion constant (*D*) and a bleaching-due-to-imaging parameter (*β*) ([Figure 5B](#fig5){ref-type="fig"}). We tested modelling of the recovery at short and long times post-bleaching. When analysing long (≥10 s) timescales, it is essential to take *β* into account, while for short times bleaching due to imaging is insignificant ([Figure 5B](#fig5){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). The Gaussian profile and the ability to fit a simple diffusion model to the recovery are strong evidence for GFP diffusion. *D*~GFP~ best-fit values (fitted to data over ∼40 s) averaged 13.2 μm^2^ s^−1^, ranging from 8.6 to 20.8 μm^2^ s^−1^ ([Table 1](#tbl1){ref-type="table"}). This matches the range 7.6--15.8 μm^2^ s^−1^ previously reported for muscle cells ([@bib2]; [@bib35]), which indicates that our approach for in vivo FRAP analysis is able to achieve similar results to those previously reported for isolated cells in culture.10.7554/eLife.06541.008Table 1.Diffusion constants, *D*, for GFP and Dystrophin in the cytoplasm obtained from fitting to FRAP experimental data**DOI:** [http://dx.doi.org/10.7554/eLife.06541.008](10.7554/eLife.06541.008)Data set number (cell number)Bleach width (pixels)Final fitted time pointFibre length (µm)Bleach position (µm)*D* (µm/s^2^)βGFP, standard fibre length set 1 (cell 1)1050090.045.09.30.001753 set 2 (cell 1)2050090.045.08.20.001572 set 3 (cell 2)1050090.045.09.60.001502 set 4 (cell 2)2050090.045.09.60.001483 set 5 (cell 3)1050090.045.06.30.002618 set 6 (cell 3)2050090.045.07.30.002503 set 7 (cell 4)1050090.045.010.20.001980 set 8 (cell 4)2050090.045.012.80.001181 set 9 (cell 5)1050090.045.012.40.002358 set 10 (cell 5)2050090.045.010.20.000961 set 1 (cell 1)1020090.045.011.00.002259 set 2 (cell 1)2020090.045.011.10.002861 set 3 (cell 2)1020090.045.010.60.001721 set 4 (cell 2)2020090.045.09.50.001418 set 5 (cell 3)1020090.045.08.60.003959 set 6 (cell 3)2020090.045.011.50.004743 set 7 (cell 4)1020090.045.09.80.001765 set 8 (cell 4)2020090.045.015.00.002000 set 9 (cell 5)1020090.045.014.40.002998 set 10 (cell 5)2020090.045.011.90.001895 set 11 (cell 6)1020090.045.016.00.001196 set 12 (cell 6)2020090.045.018.40.002364 set 1 (cell 1)105090.045.010.10.000000 set 2 (cell 1)205090.045.09.80.000000 set 3 (cell 2)105090.045.09.40.000000 set 4 (cell 2)205090.045.08.30.000000 set 5 (cell 3)105090.045.07.60.000000 set 6 (cell 3)205090.045.09.90.000000 set 7 (cell 4)105090.045.09.00.000000 set 8 (cell 4)205090.045.013.80.000000 set 9 (cell 5)105090.045.011.50.000000 set 10 (cell 5)205090.045.011.70.000000 set 11 (cell 6)105090.045.015.20.000000 set 12 (cell 6)205090.045.014.50.000000GFP, comparing measured and standard fibre length set 13 (cell 7)820082.041.013.30.001050 set 14 (cell 7)3220082.041.08.90.001208 set 15 (cell 8)820079.040.018.50.001700 set 16 (cell 8)3220079.040.010.80.002270 set 17 (cell 9)820083.030.019.80.000616 set 18 (cell 10)8200102.044.017.10.001177 set 13 (cell 7)820090.045.013.50.001084 set 14 (cell 7)3220090.045.09.00.001231 set 15 (cell 8)820090.045.019.30.001828 set 16 (cell 8)3220090.045.011.10.002377 set 17 (cell 9)820090.045.020.80.000828 set 18 (cell 10)820090.045.016.90.001144 set 13 (cell 7)85090.045.010.90.000000 set 14 (cell 7)325090.045.08.00.000000 set 15 (cell 8)85090.045.012.90.000000 set 16 (cell 8)325090.045.09.00.000000 set 17 (cell 9)85090.045.018.50.000000 set 18 (cell 10)85090.045.015.20.000000huDysGFP, standard fibre length set 19 (cell 11)820090.045.010.10.005649 set 20 (cell 11)1620090.045.06.50.005012 set 21 (cell 12)820090.045.07.20.002094 set 22 (cell 12)1620090.045.05.20.001708 set 23 (cell 13)820090.045.01.70.003047 set 24 (cell 13)1620090.045.01.80.001818 set 25 (cell 14)820090.045.09.40.008203 set 26 (cell 15)820090.045.06.00.004196 set 27 (cell 16)420090.045.01.40.001003 set 28 (cell 16)1020090.045.01.90.000966 set 19 (cell 11)85090.045.08.70.000000 set 20 (cell 11)165090.045.05.20.000000 set 21 (cell 12)85090.045.06.40.000000 set 22 (cell 12)165090.045.04.90.000000 set 23 (cell 13)85090.045.01.50.000000 set 24 (cell 13)165090.045.01.70.000000 set 25 (cell 14)85090.045.07.70.000000 set 26 (cell 15)85090.045.05.10.000000 set 27 (cell 16)45090.045.01.30.000000 set 28 (cell 16)105090.045.01.80.000000huDysGFP, comparing measured and standard fibre length set 29 (cell 17)4200130.062.01.70.001319 set 30 (cell 17)10200130.062.01.60.001140 set 31 (cell 18)4200124.049.04.00.000757 set 32 (cell 18)10200124.049.03.90.001221 set 33 (cell 19)4200106.051.05.30.001332 set 34 (cell 19)10200106.051.03.60.001408 set 35 (cell 20)10200112.031.03.40.004444 set 29 (cell 17)420090.045.01.70.001319 set 30 (cell 17)1020090.045.01.60.001140 set 31 (cell 18)420090.045.04.00.000757 set 32 (cell 18)1020090.045.03.90.001221 set 33 (cell 19)420090.045.05.30.001332 set 34 (cell 19)1020090.045.03.60.001408 set 35 (cell 20)1020090.045.03.40.004447 set 29 (cell 17)45090.045.01.40.000000 set 30 (cell 17)105090.045.01.60.000000 set 31 (cell 18)45090.045.03.60.000000 set 32 (cell 18)105090.045.03.50.000000 set 33 (cell 19)45090.045.04.00.000000 set 34 (cell 19)105090.045.03.50.000000 set 35 (cell 20)105090.045.03.10.000000[^2]

We used the FRAP method described above to analyse cytoplasmic huDysGFP dynamics. The Dystrophin profile immediately after bleaching, similar to that of GFP, is not a top-hat but a Gaussian, wider than the region actually bleached, and consistent with diffusion during the bleaching phase ([Figure 5C](#fig5){ref-type="fig"}). However, the Gaussian\'s amplitude is narrower and the depth greater for huDysGFP than GFP, consistent with slower diffusion (compare [Figure 5A,C](#fig5){ref-type="fig"}). Indeed, *D*~huDysGFP~ best-fit values (fitted to data over ∼40 s) ranged from 1.4 to 10.1 μm^2^ s^−1^, with a mean of 4.4 μm^2^ s^−1^ ([Figure 5D](#fig5){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Again, the Gaussian profile and our ability to fit a simple diffusion model to the recovery are strong evidence for huDysGFP diffusion, and rule out large scale (above μm) directed motion along the long axis of the cell, or significant binding of huDysGFP to immobile structures.

huDysGFP has significantly lower *D* than GFP, reflecting the different protein sizes of 454 kD and 27 kD, respectively ([Figure 5E](#fig5){ref-type="fig"}, p \< 0.0001). By comparing narrow and wide bleaches in the same cell across our population of muscle fibres, we found that *D*~huDysGFP~ appears to vary between cells, that is, there is real variability in huDysGFP cytoplasmic dynamics from one cell to another. The difference between *D*~huDysGFP~ values for a pair of experiments in the same cell is significantly smaller than between values in different cells ([Figure 5E,F](#fig5){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Pairs of *D* values obtained from the same cell are well correlated (*R*~huDysGFP~ = 0.9813; [Figure 5F](#fig5){ref-type="fig"}). This indicates that Dystrophin\'s diffusion in the cytoplasm shows important variations from cell to cell but that it is consistent within one cell. Further, this finding highlights the limitations of reducing noise by 'pooling' FRAP results from more than one cell. Therefore, each FRAP curve was analysed independently throughout this study and pooling was deliberately avoided. The original data and relevant analysis files for each case are available online ([@bib70]) to complement representative examples shown in figures and main data summarised in tables. We conclude that, although there is fibre-specific variation of *D*, there is no evidence that cytoplasmic Dystrophin either binds cytoskeletal elements or is actively transported towards fibre tips.

Human Dystrophin is bound at muscle fibre tips {#s2-4}
----------------------------------------------

The fibre tip region presumably contains huDysGFP bound to the Dystroglycan complex at the membrane ([@bib26]; [@bib9]) and a portion diffusing in the adjacent cytoplasm. FRAP can test whether huDysGFP is able to bind stably at the tips and reveal binding dynamics, but this is a challenging task. Diffusion of cytoplasmic protein into the bleached area, combined with bleaching-due-to-imaging, masks the real binding dynamics. We tested diffusion-plus-binding models to analyse the tip FRAP curves but these require too many variables to be reliably fitted, reflecting the complexity of the binding dynamics, as will be shown. The relatively featureless, and noisy, recovery curves of in vivo FRAP within a complex tissue cannot adequately constrain this number of variables ([@bib55]). Instead, to understand human Dystrophin dynamics at the tip, we use direct semi-quantitative analysis of bleaching and recovery. A FRAP protocol that bleached only part of the tip allowed comparison of bleached and unbleached regions of the tip ([Figure 6A](#fig6){ref-type="fig"}). We combined this with analysis of the cytoplasm intensity near the tip in each cell to measure how much recovery to expect due to diffusion. In addition, recovery is followed at an initial fast acquisition rate to detect fast recovery, and then at a slower pace over longer time periods with reduced bleaching-due-to-imaging ([Figure 6A](#fig6){ref-type="fig"}).10.7554/eLife.06541.009Figure 6.Analysis of bound Dystrophin.(**A**) FRAP protocol for tips and schematic FRAP curves showing effect of bleaching-due-to-imaging at high and low imaging frequency. Colour-coding of regions analysed in huDysGFP-expressing cell tips, correspond to traces in **A**--**E**. (**B**) Scatter plot of fractional recovery in tip pixels as a function of the cytoplasmic intensity. (**C**--**E**) Examples of normalized fluorescence curves, for tip FRAP recovery of three examples (indicated in **B**) of different tip recovery levels (**C** \> **E** \> **D**) and cytoplasmic intensity (**E** \> **C** \> **D**). Intensities in intentionally bleached region (green circles) are lower than in the unbleached tip region (red squares), yielding a difference (black crosses = red − green). Cytoplasm recovers almost fully (blue triangles). See [Table 2](#tbl2){ref-type="table"} (**C** = tip7, **D** = tip27, **E** = tip32). (**F**) Examples of unnormalized fluorescence curves for unbleached tip (squares) and cytoplasm (triangles), in tips shown in **C** (open symbols), **D** (closed symbols), and **E** (hatched symbols). Note that absolute intensity recovery in tip is larger than in the cytoplasm, but higher cytoplasmic intensity does not result in higher tip recovery (**C** vs **E**).**DOI:** [http://dx.doi.org/10.7554/eLife.06541.009](10.7554/eLife.06541.009)

On most tips, we identified three signatures of a population of Dystrophin that is bound at the tip and immobile (not turning over) on the timescale of our experiment. First, there is only partial recovery in the bleached region of the tip regardless of the huDysGFP expression levels ([Figure 6B--F](#fig6){ref-type="fig"}). Second, the normalized intensity difference between the unbleached and bleached regions in most tips (black crosses in [Figure 6C--E](#fig6){ref-type="fig"}) reaches a plateau above zero ([Table 2](#tbl2){ref-type="table"}). At the end of the experiment, both halves of the tip have received the same amount of light (and thus bleaching) for ∼250 s after the intentional bleaching phase, so the difference observed is created by the huDysGFP bleached earlier that did not turn over. Third, in the unbleached half of the tip, which receives the same bleaching-due-to-imaging as the cytoplasm, both the normalized and the absolute drops in intensity from start to end of the experiment are much larger than in the cytoplasm (compare drops in the tips with those in the cytoplasms in [Figure 6F](#fig6){ref-type="fig"}). Thus, our FRAP data consistently confirm that a population of huDysGFP is effectively bound and immobile at zebrafish muscle fibre tips.10.7554/eLife.06541.010Table 2.Analysis of FRAP data on the tips of huDysGFP-expressing cells in wild-type embryos**DOI:** [http://dx.doi.org/10.7554/eLife.06541.010](10.7554/eLife.06541.010)Tip number (cell number)Cytoplasm intensityFractional recoveryFinal normalized unbleached-bleached intensitiesUnbleached-cytoplasm 50% recovery1 (cell 1)5.800.240.14\<10 s2 (cell 1)4.580.340.23\<10 s3 (cell 2)21.580.160.25no recovery4 (cell 2)21.900.46−0.06\<20 s5 (cell 3)8.680.280.22\<10 s6 (cell 3)4.040.310.14\<10 s7 (cell 4)5.940.590.06\<10 s8 (cell 4)15.030.640.09\<10 s9 (cell 5)0.800.080.31no recovery10 (cell 5)1.810.170.36\<10 s11 (cell 6)0.470.11−0.03\<10 s12 (cell 7)−0.080.070.38\<10 s13 (cell 7)0.020.080.17\<10 s14 (cell 8)0.500.080.13\<10 s15 (cell 8)2.020.09−0.03\<10 s16 (cell 9)2.22−0.020.10\<10 s17 (cell 10)0.730.260.24\<30 s18 (cell 11)1.260.100.31\<10 s19 (cell 12)2.310.350.07\<30 s20 (cell 12)1.630.080.20\<10 s21 (cell 13)3.180.410.06\<10 s22 (cell 14)0.070.020.24\<10 s23 (cell 15)0.930.150.15\<10 s24 (cell 16)0.15−0.090.16\<30 s25 (cell 17)11.290.340.26\>30 s26 (cell 17)7.880.32−0.03\<20 s27 (cell 18)1.06−0.010.26\<10 s28 (cell 19)2.050.090.22\<20 s29 (cell 20)0.990.170.15\<10 s30 (cell 21)0.150.020.45\<10 s31 (cell 22)1.520.120.28\<20 s32 (cell 22)11.860.350.15\<10 s33 (cell 23)3.260.280.12\<10 s[^3]

Two bound populations of human Dystrophin at muscle fibre tips {#s2-5}
--------------------------------------------------------------

We analysed the dynamics of exchange of cytoplasmic freely diffusing huDysGFP with bound huDysGFP. Surprisingly, the FRAP curves revealed complex binding dynamics of Dystrophin at the tips that vary between fibres. We analysed the recovery pattern in the bleached region when switching to a slow acquisition regimen (transition from step 3 to 4 in [Figure 6A](#fig6){ref-type="fig"}). Despite the very slow turnover that characterizes the immobile-bound pool at the tips, for many fibres there is an almost immediate partial recovery (see [Figure 6C--E](#fig6){ref-type="fig"}). A shift of the dynamic equilibrium between dark-state and excitable GFP could result in apparent recovery following a switch to slow acquisition speed ([@bib48]). However, we verified that the extent to which this phenomenon occurs in huDysGFP could only justify a very small fraction of recovery (\<1%, [Figure 7A](#fig7){ref-type="fig"}). We next evaluated the contribution of free diffusion of cytoplasmic huDysGFP into the bleached region, occurring as demonstrated with a *D* around 4 μm^2^ s^−1^. As the bleached region contains bound and unbound huDysGFP and both are subjected to bleaching, it is not straightforward to analyse the recovery against a control cytoplasmic region, which is not subjected to intentional bleaching. Therefore, we compared unbleached tip and cytoplasm traces, which were submitted to comparable experimental conditions, without intentional bleaching but with strong bleaching-due-to-imaging during the fast acquisition phase ([Figure 6F](#fig6){ref-type="fig"}). On switching to slow acquisition, any recovery on the unbleached tip would be expected to parallel the recovery on the cytoplasm. Nevertheless, the immediate recovery is in most cases larger than that expected from diffusion of cytoplasmic huDysGFP despite a steady state is reached soon after, characteristic of the large immobile pool ([Figure 6F](#fig6){ref-type="fig"}, compare open or hatched squares \[unbleached tip\] with the respective open or hatched triangles \[cytoplasm\]). In most cases, at least 50% of the total recovery of unnormalised unbleached minus cytoplasm curves occur within 10 s ([Table 2](#tbl2){ref-type="table"}). This indicates that there is an unaccounted third pool of huDysGFP, in addition to the immobile-bound pool and the cytoplasmic-free diffusible pool: a rapidly turning-over dynamic bound huDysGFP pool.10.7554/eLife.06541.011Figure 7.Effect of dark state and lateral mobility on huDysGFP intensity recovery.(**A**) To evaluate the recovery fraction due to dark state, huDysGFP was bleached in entire muscle fibres in vivo. Images shown were taken at *t* = 0 (top panel) and right after bleaching (middle panel); the red line defines the bleached region. Lower panel: plot of normalised fluorescence shows very low recovery after photobleaching (0.6%), presumably due to a shift from dark state to excitable huDysGFP. (**B**) FRAP tests for lateral mobility of bound huDysGFP. Top panel: initial image acquired from muscle fibre tip 7 showing the area to be bleached in green and the unbleached tip region in red. Middle and bottom panels: one-dimensional profiles along *X*~T~ for an example of substantial recovery (middle panel, tip7) and little recovery (bottom panel, tip27). Profiles are shown at three time points: before deliberate bleaching (*t* = 0.93 s, black squares), just after bleaching (*t* = 5.3 s, orange triangles), and at the end of the experiment (*t* = 230 s, turquoise crosses). The intensity at each point is the average (background corrected) unnormalized intensity over the 20 pixel strip along the *Y*~T~ axis and averaged over 3 images, at the given time, plus the previous and next images.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.011](10.7554/eLife.06541.011)

Recovery that is presumably due to the bound mobile pool is seen in fibres with no detectable or very low levels of cytoplasmic unbound huDysGFP ([Table 2](#tbl2){ref-type="table"}). However, the extent of the recovery is still dependent on the amount of cytoplasmic huDysGFP in a fibre ([Figure 6B,F](#fig6){ref-type="fig"}). Note that in the scatter plot of fractional recovery against cytoplasmic huDysGFP intensity, fibre tips with negligible cytoplasmic huDysGFP show very low recovery ([Figure 6B](#fig6){ref-type="fig"}). This suggests that cytoplasmic protein is required for the dynamic recovery. Interestingly, tips with high cytoplasmic huDysGFP intensity near the tip do not necessarily recover more (compare [Figure 6C,E,F](#fig6){ref-type="fig"}) indicating real tip-to-tip variation in the dynamic bound pool. The two tips of the same fibre behave similarly in some but not all cases ([Table 2](#tbl2){ref-type="table"}).

Most of the recovery that is detected occurs within a few seconds in most cases ([Table 2](#tbl2){ref-type="table"}). Given that *D*~huDysGFP~ is a few μm^2^ s^−1^, diffusion times across the tip region will be of order a second. Thus, recovery of the dynamic bound pool is fast enough that it may be limited by diffusion. If there is a characteristic binding lifetime, it is at most a few seconds. In summary, our data indicate that most fibres have two pools of huDysGFP bound at their tips, a tightly bound pool stable for at least minutes and another with a sub-second to a few seconds turnover time.

Lateral immobility of bound Dystrophin {#s2-6}
--------------------------------------

To confirm that the mobility of bound Dystrophin can only be due to exchange with the free-diffusing pool, we tested for lateral mobility of bound huDysGFP, that is, we searched for evidence that huDysGFP can move along the membrane without unbinding and becoming part of the cytoplasmic pool. We examined intensity profiles along the *X*~T~ axis, parallel to the tip membrane ([Figure 7B](#fig7){ref-type="fig"} and [Figure 4D](#fig4){ref-type="fig"}). After deliberately bleaching part of the tip, we looked for a gradient in fluorescence recovery along *X*~T~ that could arise from mobility of bound Dystrophin. If the bound Dystrophin is mobile at the tip in the plane of the membrane, bleached bound huDysGFP would leave the deliberately bleached half of the tip and be replaced by fluorescent huDysGFP from the unbleached half. This would help drive fluorescence recovery and would be especially pronounced at the boundary between the bleached and unbleached halves of the tip, generating a gradient of fluorescence along the *X*~T~ axis. We see no evidence of such gradients ([Figure 7B](#fig7){ref-type="fig"}). In particular, in the middle panel of [Figure 7B](#fig7){ref-type="fig"}, although there is substantial recovery (compare the turquoise crosses with the immediately post-bleach orange triangles), there is no overall tendency in the intensity in the unbleached part of the tip to decrease from right to left as the bleached tip area is approached. The same applies to cases of little recovery ([Figure 7C](#fig7){ref-type="fig"}), where only substantial bleaching-due-to-imaging is observed on the unbleached tip half. The lack of evidence of lateral mobility of bound huDysGFP argues in favour of the existence of a bound-mobile pool with a fast turnover rate responsible for the fast fluorescence recovery observed in most fibres.

Human Dystrophin efficiently rescues zebrafish dystrophic embryos and two bound pools are still found in the absence of competition with endogenous Dystrophin {#s2-7}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

The experiments above were performed in wild-type zebrafish embryos. We asked whether the mobile-bound Dystrophin pool observed may result from competition of the exogenous human Dystrophin with endogenous zebrafish Dystrophin. To address this question, huDysGFP was expressed in Dystrophin-null zebrafish embryos (*dmd*^*ta222a/ta222a*^).

We first evaluated the ability of human Dystrophin to rescue the zebrafish dystrophic fibres. Typically, in the absence of Dystrophin, the zebrafish muscle fibres detach upon contraction. At 3 days post fertilisation, nearly all *dmd*^*ta222a/ta222a*^ embryos show signs of dystrophy ([Figure 8A](#fig8){ref-type="fig"}). To quantify rescue efficiency, we first evaluated the percentage of cells that detach by mosaically expressing GFP in *dmd*^*ta222a/ta222a*^ embryos. Injecting a GFP control plasmid did not affect muscle fibres in siblings (N = 39), but about 23% of the GFP positive fibres in *dmd*^*ta222a/ta222a*^ embryos detached ([Figure 8B](#fig8){ref-type="fig"}). In marked contrast, cells expressing huDysGFP looked healthy and no detachment was found, suggesting full rescue of the dystrophic phenotype in *dmd*^*ta222a/ta222a*^ muscle fibres ([Figure 8B](#fig8){ref-type="fig"}; p = 0.000126 in Chi-square test for significance between GFP and huDysGFP).10.7554/eLife.06541.012Figure 8.huDysGFP rescuing and binding dynamics in *dmd*^*ta222a/ta222a*^ embryos.(**A**) 3 dpf *dmd*^*ta222a/ta222a*^ zebrafish embryo with typical dystrophic muscles as shown by *actc1b:mCherry* reporter (red) in vivo, with several healthy fibres expressing huDysGFP (green). (**B**) Control GFP mosaically expressed in *dmd*^*ta222a/ta222a*^ embryos is found in both healthy (77%) and dystrophic (23%) fibres (N = 56). Expression of huDysGFP fully rescues the dystrophic phenotype in *dmd*^*ta222a/ta222a*^ muscle fibres, as no cells expressing huDysGFP were found detached or unhealthy in any visible aspect (N = 56). p = 0.000126 in Chi-square test for significance between GFP and huDysGFP. GFP and huDysGFP-positive cells in regions of very dystrophic muscles in *dmd*^*ta222a/ta222a*^ zebrafish embryos are shown. The *actc1b:mCherry* reporter filling up the cytoplasm and huDysGFP expression at the tip suggest that the fibre structure is kept intact even without support from neighbouring cells, unlike the GFP-positive cell. (**C**) huDysGFP ratio tip intensity/cytoplasm intensity in wild-type (mean = 3.7 ± 1.1 s.e.m.; n = 33) and *dmd*^*ta222a/ta222a*^ (mean = 9.6 ± 3.2 s.e.m.; n = 13) zebrafish embryos. In the wild-type background, where huDysGFP competes with endogenous Dystrophin for available binding sites, the average ratio is 2.5 times lower than in the mutant background (p = 0.03), where huDysGFP can occupy all available sites. (**D**) Scatter plot of fractional recovery in bleached tip pixels as a function of the cytoplasmic intensity. (**E**) Comparative scatter plots, with mean and SD, of huDysGFP fractional recovery in bleached tip pixels in wild-type (wt), *dmd*^*ta222a/ta222a*^ (dmd) and their siblings (sibs). There were no statistically significant differences between groups as determined by one-way ANOVA \[F(2,67) = 0.8628, ns\]. (**F**) Comparative scatter plots, with mean and SD, of huDysGFP final unbleached tip minus bleached tip intensities in wild-type (wt), *dmd*^*ta222a/ta222a*^ (dmd) and their siblings (sibs). There were no statistically significant differences between groups as determined by one-way ANOVA \[F(2,67) = 2.845, ns\]. (**G**) huDysGFP fraction of cases showing no recovery, or 50% recovery at the first (\<10 s), second (\<20 s), or later (\>20 s) time points, calculated from unbleached tip minus bleached tip intensities, in wild-type (wt), *dmd*^*ta222a/ta222a*^ (dmd) and their siblings (sibs). There were no statistically significant differences between groups as determined by one-way ANOVA \[F(2,67) = 0.1521, ns\]. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.012](10.7554/eLife.06541.012)

Next, huDysGFP intensity in the whole fibre and locally at the fibre tips was measured in wild-type embryos, where it coexists with the endogenous Dystrophin and in *dmd*^*ta222a/ta222a*^ dystrophic embryos ([Figure 8C](#fig8){ref-type="fig"}). In the absence of competition with the endogenous protein, huDysGFP appears to occupy more of the available binding sites, showing a 2.5-fold increase in the intensity ratio tips:cytoplasm compared to that found in wild-type background. This indicates that fibres expressing the same intensity in the cytoplasm can accumulate more at the fibre tips in the mutant background, consistent with the view that huDysGFP overexpression in the wild-type background does not displace all endogenous zebrafish Dystrophin.

Finally, tip FRAP curves of huDysGFP in *dmd*^*ta222a/ta222a*^ and siblings were analysed. Regardless of the genotype, most tips show the three typical signatures of an immobile-bound population described above: only partial recovery in the tip bleached region independently of the cytoplasmic intensity ([Figure 8D,E](#fig8){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}), the normalized intensity difference between the unbleached and bleached regions in most tips reaches a plateau above zero ([Figure 8F](#fig8){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}), and unbleached tip half intensity shows higher drop than the cytoplasm in the fast acquisition phase (see original curves in [@bib70]). Also regardless of the genotype, the tip intensity registers a rapid recovery that is uncharacteristic of an immobile fraction while higher than the estimated contribution of the cytoplasmic pool. Evidence is clear when comparing events on switching between fast and slow acquisition in the unbleached tip half and cytoplasm unnormalised intensity curves. At least 50% of the total recovery occurs within 10 s in most fibre tips, too fast for the immobile-bound pool ([Figure 8G](#fig8){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). Overall, our analysis found no significant differences between huDysGFP binding dynamics in wild-type, *dmd*^*ta222a/ta222a*^ or their siblings. These results suggest that the presence of two bound populations of huDysGFP with different turnover times is not due to competition with endogenous zebrafish Dystrophin.10.7554/eLife.06541.013Table 3.Analysis of FRAP data on the tips of huDysGFP-expressing cells in *dmd*^*ta222a/ta222a*^ embryos and siblings**DOI:** [http://dx.doi.org/10.7554/eLife.06541.013](10.7554/eLife.06541.013)Tip numberEmbryo genotypeCytoplasm intensityFractional recoveryFinal normalized unbleached-bleached intensitiesUnbleached-cytoplasm 50% recovery1*dmd*^*ta222a/ta222a*^51.560.120.18\<10 s2*dmd*^*ta222a/ta222a*^23.120.100.31\<10 s3*dmd*^*ta222a/ta222a*^38.040.070.25no recovery4*dmd*^*ta222a/ta222a*^83.990.250.02\<10 s5*dmd*^*ta222a/ta222a*^4.460.060.30\<10 s6*dmd*^*ta222a/ta222a*^0.34−0.010.21\<10 s7*dmd*^*ta222a/ta222a*^3.160.210.17\<20 s8*dmd*^*ta222a/ta222a*^16.490.160.24\<10 s9*dmd*^*ta222a/ta222a*^18.670.060.07\<10 s10*dmd*^*ta222a/ta222a*^8.730.200.25\<10 s11*dmd*^*ta222a/ta222a*^7.120.470.12\<20 s12*dmd*^*ta222a/ta222a*^11.060.170.15\<20 s13*dmd*^*ta222a/ta222a*^10.650.090.23\<10 s14*dmd*^*ta222a/ta222a*^28.410.020.13\<20 s15*dmd*^*ta222a/ta222a*^8.910.170.14\<10 s16*dmd*^*ta222a/ta222a*^41.160.240.16\<10 s17*dmd*^*ta222a/ta222a*^17.710.360.50\<20 s18*dmd*^*ta222a/ta222a*^20.430.250.36\<10 s19sibling30.85−0.020.20\<10 s20sibling45.810.120.17\<30 s21sibling13.890.110.23\<10 s22sibling7.050.100.33\<10 s23sibling12.780.010.32\<10 s24sibling6.480.090.26\<10 s25sibling10.950.070.28\<10 s26sibling8.350.200.22\<10 s27sibling10.140.150.15\<10 s28sibling7.150.110.50\<10 s29sibling7.770.060.57\<10 s30sibling19.640.160.18\<10 s31sibling16.080.320.36\<10 s32sibling8.110.130.37\<10 s33sibling7.300.200.36\<10 s34sibling14.990.400.06\<20 s35sibling29.820.280.06\<20 s36sibling9.950.340.18\<10 s37sibling32.10−0.020.12\<10 s[^4]

Two bound populations also characterize the dynamics of zebrafish Dystrophin-GFP {#s2-8}
--------------------------------------------------------------------------------

We asked whether the labile membrane-bound pool may be a consequence of weaker binding between the human Dystrophin protein and the zebrafish endogenous protein complexes. To address this question, we analysed the dynamics of overexpressed zebrafish Dystrophin: GFP-tagged zebrafish Dystrophin (zfDysGFP). Similar to huDysGFP, the overexpression of zfDysGFP results in mosaic expression and variable levels of accumulation both at the muscle fibre tips and cytoplasm ([Figure 9A](#fig9){ref-type="fig"}; [Table 4](#tbl4){ref-type="table"}). The cytoplasmic zfDysGFP diffusion dynamics was analysed by FRAP. *D*~zfDysGFP~ best-fit values (fitted to data over ∼40 s) ranged from 0.6 to 6.7 μm^2^ s^−1^, with a mean of 2.9 μm^2^ s^−1^ ([Figure 9B](#fig9){ref-type="fig"}). zfDysGFP has statistically significantly lower *D* than GFP (p \< 0.001) but shows no difference with huDysGFP ([Figure 9B](#fig9){ref-type="fig"}).10.7554/eLife.06541.014Figure 9.zfDysGFP dynamics in wild-type and *dmd*^*ta222a/ta222a*^ embryos.(**A**) zfDysGFP variable intensity of expression in muscle fibres of 2 dpf wild-type embryo. Arrows point to low and arrowheads to high expressing tips. (**B**) Comparative scatter plots of *D*~*GFP*~, *D*~*huDysGFP*~ and *D*~*zfDysGFP*~. One-way ANOVA revealed a statistically significant difference between groups \[F(2,44) = 57.08, p \< 0.0001\]. Tukey post-hoc test revealed that *D*~*huDysGFP*~ (4.4 ± 2.7 μms^2^s^−1^) and *D*~*zfDysGFP*~ (2.9 ± 1.7 μms^2^s^−1^) are not statistically significant but are statistically significantly lower (p \< 0.001) than *D*~*GFP*~ (13.2 ± 3.7 μms^2^s^−1^). (**C**) A rescued zfDysGFP (green) fibre within a 2 dpf *dmd*^*ta222a/ta222a*^ zebrafish embryo with otherwise typical dystrophic muscles as shown by *actc1b:mCherry* (red, note extensive gaps in muscle) reporter in vivo. (**D**) Scatter plot of fractional recovery in bleached tip pixels as a function of the cytoplasmic intensity. (**E**) Comparative scatter plots, with mean and SD, of the fractional recovery in bleached tip pixels of huDysGFP in wild-type (wt) embryos, and zfDysGFP in wild-type and *dmd*^*ta222a/ta222a*^ (dmd) embryos. There were no statistically significant differences between groups as determined by one-way ANOVA \[F(2,70) = 3.019, ns\]. (**F**) Comparative scatter plots, with mean and SD, of final unbleached tip minus bleached tip intensities of huDysGFP in wild-type embryos, and zfDysGFP in wild-type and *dmd*^*ta222a/ta222a*^ embryos. One-way ANOVA revealed a statistically significant difference between groups \[F(2,70) = 6.818, p = 0.002\]. Tukey post-hoc test revealed that zfDysGFP in wild-type (0.3 ± 0.16, n = 22) and *dmd*^*ta222a/ta222a*^ embryos (0.3 ± 0.1, n = 18) are not statistically significant but huDysGFP (0.17 ± 0.12, n = 33) is statistically significantly lower than zfDysGFP in wild-type (p \< 0.01) and in *dmd*^*ta222a/ta222a*^ embryos (p \< 0.05). (**G**) Fraction of cases showing no recovery, or 50% recovery at the first (\<10 s), second (\<20 s), or later (\>20 s) time points, calculated from unbleached tip minus bleached tip intensities, in huDysGFP in wild-type embryos, and zfDysGFP in wild-type and *dmd*^*ta222a/ta222a*^ embryos. There were no statistically significant differences between groups as determined by one-way ANOVA \[F(2,70) = 1.405, ns\]. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.014](10.7554/eLife.06541.014)10.7554/eLife.06541.015Table 4.Analysis of FRAP data on the tips of zfDysGFP-expressing cells in wild-type and *dmd*^*ta222a/ta222a*^ embryos**DOI:** [http://dx.doi.org/10.7554/eLife.06541.015](10.7554/eLife.06541.015)Tip number (cell number)Embryo genotypeCytoplasm intensityFractional recoveryFinal normalized unbleached-bleached intensitiesUnbleached-cytoplasm 50% recovery1 (cell 1)wild type14.590.080.46\<10 s2 (cell 2)wild type5.060.070.24\<10 s3 (cell 3)wild type9.440.170.12\<20 s4 (cell 4)wild type6.510.170.38\<10 s5 (cell 4)wild type8.020.300.05\<10 s6 (cell 5)wild type79.280.040.22\<10 s7 (cell 6)wild type1.780.090.51\<20 s8 (cell 6)wild type1.010.120.38\<10 s9 (cell 7)wild type0.280.210.13\<10 s10 (cell 8)wild type27.460.050.16\<10 s11 (cell 9)wild type12.130.080.17\<10 s12 (cell 9)wild type17.340.120.40\<10 s13 (cell 10)wild type5.090.130.23\<10 s14 (cell 10)wild type2.140.030.34\<10 s15 (cell 11)wild type−0.130.130.80\<10 s16 (cell 12)wild type2.090.060.17\<10 s17 (cell 12)wild type1.940.040.31\<10 s18 (cell 13)wild type5.800.030.29\<10 s19 (cell 13)wild type6.65−0.040.32\<10 s20 (cell 14)wild type6.420.270.31\<10 s21 (cell 14)wild type6.87−0.020.35\<10 s22 (cell 15)wild type8.960.250.23\<10 s23 (cell 16)*dmd*^*ta222a/ta222a*^11.400.420.25\<10 s24 (cell 17)*dmd*^*ta222a/ta222a*^4.700.050.35\<10 s25 (cell 17)*dmd*^*ta222a/ta222a*^3.810.010.40\<10 s26 (cell 18)*dmd*^*ta222a/ta222a*^6.770.330.12\<10 s27 (cell 19)*dmd*^*ta222a/ta222a*^−0.38−0.020.36\<10 s28 (cell 19)*dmd*^*ta222a/ta222a*^−0.600.110.32\<10 s29 (cell 20)*dmd*^*ta222a/ta222a*^4.860.120.38\<10 s30 (cell 21)*dmd*^*ta222a/ta222a*^3.450.470.24\<10 s31 (cell 21)*dmd*^*ta222a/ta222a*^3.600.470.25\<10 s32 (cell 22)*dmd*^*ta222a/ta222a*^7.600.390.10\<10 s33 (cell 23)*dmd*^*ta222a/ta222a*^26.070.190.18\<10 s34 (cell 24)*dmd*^*ta222a/ta222a*^6.080.150.45\<10 s35 (cell 24)*dmd*^*ta222a/ta222a*^8.030.070.38no recovery36 (cell 25)*dmd*^*ta222a/ta222a*^17.930.280.22\<10 s37 (cell 26)*dmd*^*ta222a/ta222a*^6.210.120.23\<10 s38 (cell 27)*dmd*^*ta222a/ta222a*^5.620.070.13\<20 s39 (cell 28)*dmd*^*ta222a/ta222a*^6.880.230.22\<10 s40 (cell 29)*dmd*^*ta222a/ta222a*^23.050.170.29\<20 s[^5]

Next, we analysed zfDysGFP dynamics at the fibre tips, in a wild-type context, where it competes for binding with endogenous Dystrophin, or in *dmd*^*ta222a/ta222a*^ mutants ([Figure 9A,C](#fig9){ref-type="fig"}). Exogenous zfDysGFP is able to rescue the dystrophic phenotype in *dmd*^*ta222a/ta222a*^ mutants (32/32, p = 0.003; [Figure 9C](#fig9){ref-type="fig"}). Like huDysGFP, most zfDysGFP tips show the typical signatures of an immobile-bound population regardless of the genotype ([Figure 9D--F](#fig9){ref-type="fig"}; [Table 4](#tbl4){ref-type="table"}). There are no statistically significant differences between the fractional recoveries of Dystrophin of the different species and in the different genetic backgrounds ([Figure 9E](#fig9){ref-type="fig"}). However, the final unbleached minus bleached intensity of huDysGFP is statistically significantly lower than zfDysGFP ([Figure 9F](#fig9){ref-type="fig"}). Using a two-way ANOVA to test the effect of genotypic background (wild-type or *dmd*^*ta222a/ta222a*^) and Dystrophin origin (human or zebrafish) on the immobile fraction, we observed a significant effect of Dystrophin origin (human vs zebrafish) \[F(1,87) = 11.21, p = 0.0012\] but not of the host genotype \[F(1,87) = 0.02326, p = 0.8791\], and there was no significant interaction between origin and genotype \[F(1,87) = 1.367, p = 0.2455\]. While a final unbleached minus bleached intensity above zero indicates the existence of an immobile-bound fraction, its value is not a direct measurement of the amount of immobile-bound Dystrophin. However, we cannot exclude the possibility that huDysGFP forms less, or less stable, immobile-bound links than zfDysGFP, in the zebrafish environment. The background genotype appears not to influence this trait, suggesting that if there is a difference in the immobile fraction that is independent from competition with endogenous Dystrophin.

Like huDysGFP, most zfDysGFP-expressing fibres show a fast recovery phase that is higher than the estimated contribution of the cytoplasmic pool. Typically, at least 50% of the total recovery of unbleached tip half minus cytoplasm intensity curves occurs within 10 s in the majority of the cases, regardless of species and genotype ([Figure 9G](#fig9){ref-type="fig"}; [Table 4](#tbl4){ref-type="table"}). This recovery is very fast and the characteristic immobile pool plateau is soon reached, suggesting the existence of an additional bound pool of zfDysGFP with rapid turnover. These results show that, like huDysGFP, zfDysGFP can be found in three populations, one diffusible and two bound with different binding lifetimes. Therefore, regardless of any differences between huDysGFP and zfDysGFP, our results confirm that the mobile-bound pool previously found for the human Dystrophin is not caused by weaker interactions with a different species environment.

Endogenous zebrafish Dystrophin diffusion and binding dynamics {#s2-9}
--------------------------------------------------------------

Analysis of FRAP curves of both huDysGFP and zfDysGFP indicated that when a low level of diffusible Dystrophin is detected in cytoplasm, there can be a significant amount of bound-mobile pool. However, there is the possibility that the labile-bound pool is caused by an excess of cytoplasmic Dystrophin resulting from overexpression. We questioned whether a mobile-bound pool can also be found in endogenous zebrafish Dystrophin, where a cytoplasmic pool of the protein is not known. We have analysed *Gt(dmd-Citrine)*^*ct90a*^ zebrafish embryos, in which Citrine was inserted by gene-trap into the endogenous Dystrophin locus, creating fluorescently tagged zfDys ([@bib60]; [@bib52]).

We first searched for signs of cytoplasmic Dystrophin. As every muscle fibre expresses Citrine-tagged Dystrophin (zfDysCitrine; [Figure 10A](#fig10){ref-type="fig"}), and different tissues may have different background fluorescence, it is not easy to evaluate with confidence whether there are low levels of cytoplasmic zfDysCitrine above the background. We hypothesized that if there is zfDysCitrine in the cytoplasm, we should register a recovery after photobleaching. Control siblings lacking zfDysCitrine show a flat and noisy FRAP curve that reflects the background fluorescence ([Figure 10B](#fig10){ref-type="fig"}, plot a). In contrast, the very low zfDysCitrine intensity detected in the cytoplasm could be bleached to even lower levels, and a recovery curve is registered, indicating the presence of diffusible zfDysCitrine in the cytoplasm ([Figure 10B](#fig10){ref-type="fig"}, plot b). The switch from a dark state of Citrine was evaluated and contributes little to the recovery ([Figure 10B](#fig10){ref-type="fig"}, plot c). Another signature of the presence of diffusible zfDysCitrine was the inverted bell-shaped, instead of top-hat, Gaussian curve that results from diffusion during intentional bleaching ([Figure 10C](#fig10){ref-type="fig"}). Finally, zfDysCitrine recovery curves can be fit using a diffusion model ([Figure 10D](#fig10){ref-type="fig"}). *D*~*zfDysCitrine*~ best-fit values ranged from 0.9 to 4.3 μm^2^ s^−1^ and mean 2.2 μm^2^ s^−1^ ([Figure 10E](#fig10){ref-type="fig"}). There is no significant statistical difference between *D*~*zfDysCitrine*~ and *D*~*zfDysGFP*~.10.7554/eLife.06541.016Figure 10.Endogenously driven zfDysCitrine dynamics.(**A**) In vivo zfDysCitrine (green) expression in muscle fibres of 2 dpf *Gt(dmd-citrine)^ct90a^* embryo contrasted with transmitted light. (**B**) Schematics of zebrafish muscle fibres showing origin of scatter plots a, b, and c. Bleaching a region in the cytoplasm of Citrine-negative siblings (a) results in a flat curve of background fluorescence intensity, while the same experiment in Citrine-positive embryos (b) results in a significant drop in fluorescence followed by recovery. Bleaching a large region to include the entire fibre abolishes recovery (c), indicating that recovery from a citrine dark state makes a negligible contribution to recovery in (b). (**C**, **D**) Normalized FRAP experimental data and fitting curves of a zfDysCitrine fibre cytoplasm. (**C**) Normalized intensity profile along the *X*-axis at the first time point after bleaching (dots) and Gaussian fit (red line). (**D**) Recovery curves along *X*-axis (dots) and fit of the diffusion model to the post-bleach (red line). (**E**) Comparative scatter plots of *D*~*zfDysGFP*~ and *D*~*zfDysCitrine*~. *t* test shows no statistically significant differences. (**F**) Scatter plot of fractional recovery in bleached tip pixels as a function of the cytoplasmic intensity, for zfDysCitrine embryos of different developmental stages. HS = heat-shocked embryos. (**G**) Comparative scatter plots, with mean and SD, of the fractional recovery in bleached tip pixels of zfDysGFP and zfDysCitrine. *t* test shows no statistically significant difference. (**H**) Comparative scatter plots, with mean and SD, of final unbleached tip minus bleached tip intensities of zfDysGFP and zfDysCitrine. *t* test shows no statistically significant differences. (**I**) Fraction of cases showing no recovery, or 50% recovery at the first (\<10 s), second (\<20 s), or later (\>20 s) time points, calculated from unbleached tip minus bleached tip intensities, in zfDysGFP and zfDysCitrine. **t** test shows a statistically significant difference (p = 0.0016). Scale bar = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.016](10.7554/eLife.06541.016)

To be able to analyse single fibres, some embryos were subjected to heat shock, which causes mosaic disruption of the somites ([@bib52]). Embryos not subjected to heat shock, at different developmental stages (30 hpf, 40 hpf and 48 hpf) were also analysed. However, no trend was obvious when analysing embryos of different developmental stages ([Figure 10F](#fig10){ref-type="fig"}; [Table 5](#tbl5){ref-type="table"}). Most tips showed the typical signatures of an immobile-bound pool, as expected, and no statistically significant differences were found between zfDysGFP and zfDysCitrine ([Figure 10F--H](#fig10){ref-type="fig"}; [Table 5](#tbl5){ref-type="table"}). There is fractional recovery in most bleached tips that tends to be low ([Figure 10F](#fig10){ref-type="fig"}, [Table 5](#tbl5){ref-type="table"}), which in accordance with the results obtained for huDysGFP and zfDysGFP cases when the cytoplasm intensity is just above detectable ([Figures 6B, 8D, 9D](#fig6 fig8 fig9){ref-type="fig"}; [Tables 2--4](#tbl2 tbl3 tbl4){ref-type="table"}). Therefore, we found no indications that endogenous zfDysCitrine behave differently from exogenous zfDysGFP regarding their immobile pool signatures.10.7554/eLife.06541.017Table 5.Analysis of FRAP data on the tips of ZfDysCitrine expressing cells in *Gt(dmd-Citrine)*^*ct90a*^ embryos**DOI:** [http://dx.doi.org/10.7554/eLife.06541.017](10.7554/eLife.06541.017)Tip numberSetCytoplasm intensityFractional recoveryFinal normalized unbleached-bleached intensitiesUnbleached-cytoplasm 50% recovery1heat shock1.71−0.040.37\<20 s2heat shock1.850.150.14\<20 s3heat shock0.370.100.39\<20 s4heat shock3.520.090.14\<30 s5heat shock0.980.130.17\<20 s6heat shock0.870.070.21\<20 s7heat shock1.300.130.17\<10 s848 hpf4.300.050.36\<10 s948 hpf3.110.040.37\<10 s1048 hpf1.720.120.53\<20 s1148 hpf2.090.040.39\<20 s1248 hpf2.010.070.42\<10 s1348 hpf6.21−0.020.41\<10 s1440 hpf3.260.100.27\<20 s1540 hpf0.720.140.25\<30 s1640 hpf3.570.030.26\<20 s1740 hpf4.950.080.22\<20 s1840 hpf0.790.010.25\<10 s1940 hpf0.090.030.28\<20 s2030 hpf1.530.070.38\<10 s2130 hpf1.600.060.48\<60 s2230 hpf5.020.090.50\<20 s2330 hpf2.660.090.64\<40 s2430 hpf3.040.110.44\<10 s2530 hpf3.190.070.37\<10 s2630 hpf2.780.030.28\<10 s[^6]

Despite the low cytoplasmic intensity, many zfDysCitrine tips still show a very fast recovery. At least 50% of the total recovery of the unbleached tip half minus the cytoplasm happens in almost half of the cases within 10 s, and still very fast at less than 20 s in the majority of the remaining cases ([Figure 10I](#fig10){ref-type="fig"}; [Table 5](#tbl5){ref-type="table"}). This suggests the presence of a mobile-bound pool, regardless of the statistically significant difference in the time it takes for zfDysCitrine and zfDysGFP to recover (p = 0.0016). The tendency to take longer to recover is likely to reflect the dependency of the mobile-bound pool on cytoplasmic availability of free Dystrophin. This is in accordance with our previous observations that recovery of the mobile-bound pool is fast enough that it may be limited by diffusion. The data therefore indicate that endogenous Dystrophin with an inserted Citrine, like exogenous zfDysGFP and huDysGFP, can be found in two states, immobile and mobile, regardless of a very low, but detectable, cytoplasmic pool.

Discussion {#s3}
==========

Altogether, our results show that Dystrophin can exist in three populations in muscle cells in vivo: one freely diffusing in the cytoplasm, a second stably anchored at the plasma membrane that shows no lateral diffusion, and a third, dynamically bound to the plasma membrane. A stable-bound pool is consistent with Dystrophin\'s well-described function of sustaining mechanical stability upon muscle contraction ([@bib29]; [@bib43]; [@bib23]; [@bib53], [@bib54]). Additionally, the presence of a dynamic pool with weak and short-term binding points to a new aspect of Dystrophin biology. Based on these results, we propose a model for Dystrophin association with the membrane ([Figure 11](#fig11){ref-type="fig"}). Even very low levels of freely diffusible cytoplasmic Dystrophin can stochastically bind to molecules at the plasma membrane, entering a mobile-bound state ([Figure 11](#fig11){ref-type="fig"}, arrows). This may represent an intermediate state towards Dystrophin stabilization, possibly more abundant in the immature fibres of the developing embryo ([Figure 11](#fig11){ref-type="fig"}, dashed arrow 1). Alternatively, Dystrophin may coexist in two distinct bound forms with specific roles, possibly reflecting the mature state of the membrane association.10.7554/eLife.06541.018Figure 11.Model for Dystrophin membrane association.Dystrophin is present in three states: cytoplasmic, bound mobile, and bound immobile. Switching between cytoplasmic and bound mobile (solid arrows) occurs at a rate of under a few seconds, limited by the diffusion rate. Immobile Dystrophin is stably bound for at least several minutes. Dashed arrows represent three possible routes to stable Dystrophin complex formation: (1) from a bound mobile Dystrophin intermediate, (2) by direct addition from the cytoplasmic pool, (3) by anchoring of nascent Dystrophin polypeptide chains from localized mRNA. These possibilities are not mutually exclusive.**DOI:** [http://dx.doi.org/10.7554/eLife.06541.018](10.7554/eLife.06541.018)

Validating Dystrophin over-expression in zebrafish as a model system to study Dystrophin dynamics in vivo {#s3-1}
---------------------------------------------------------------------------------------------------------

In various fields, transgenic and humanized animal models are a valuable resource where non-invasive methods to study human biology are lacking ([@bib10]; [@bib3]; [@bib1]). Here, we show that exogenous zebrafish and human Dystrophin have subcellular localizations, at both mRNA and protein levels, equivalent to that of endogenous Dystrophin ([@bib52]). Furthermore, exogenous zebrafish and human Dystrophin have diffusion and binding dynamics similar to those of endogenous zebrafish Dystrophin, in spite of the artificially raised cytoplasmic levels caused by over-expression. Furthermore, we found that Dystrophin dynamics is not affected by the position of the fluorescent tag (internally close to the actin binding site \[Citrine\] or in C-terminal position \[GFP\]). Importantly, both zebrafish and human Dystrophins were able to rescue the dystrophic phenotype of *dmd*^*ta222a/ta222a*^ embryos. Taken together, these data indicate that the zebrafish embryo is a good model system to study the dynamics of human Dystrophin in live muscle cells in vivo using fluorescently tagged versions of the protein. It is important to keep in mind that human Dystrophin may behave differently in zebrafish than in human muscle. The FRAP analysis methodology developed in this study could be applied for studies on human primary muscle cell cultures, or even pluripotent human stem cells differentiated into muscle fibres ([@bib14]). However, until a suitable 3D ex-vivo physiologically relevant human muscle system is readily available for routine experimentation, our methodology and findings provide a baseline for future comparative studies. For instance, the strategy presented here can be used to study the effects of shortening the protein on Dystrophin dynamics, as occurs in patients with BMD and planned exon-skipping gene therapies ([@bib37]; [@bib17]; [@bib38]; [@bib61]).

Cytoplasmic Dystrophin {#s3-2}
----------------------

We show that, in all three experimental conditions used (exogenous zfDysGFP and huDysGFP or endogenously-driven zfDysCitrine), part of Dystrophin is found in a cytoplasmic freely diffusing pool. Despite considerable apparent variation in measured diffusion constant (*D*) from fibre to fibre (1.4--10.1 μm^2^ s^−1^ for *D*~*huDysGFP*~, 0.6 to 6.7 μm^2^ s^−1^ for *D*~*zfDysGFP*~, 0.9 to 4.3 μm^2^ s^−1^ for *D*~*zfDysCitrine*~, mean 4 μm^2^ s^−1^, 3 μm^2^ s^---1^, and 2 μm^2^ s^---1^, respectively), it is clear that the mobility of Dystrophin is on average around a fourth that of GFP, at approximately 13 μm^2^ s^−1^. However, whereas GFP is a small (3 × 3 × 4 nm) globular protein, Dystrophin is thought to be a rod perhaps 100 nm long ([@bib51]; [@bib2]; [@bib8]; [@bib33]; [@bib35]), so a diffusion constant only a quarter that of GFP is surprising. As Dystrophin appears to diffuse, perhaps so-called 'active diffusion' due to energy-using cellular processes (e.g., molecular motors) enhances its apparent mobility in a non-directed manner ([@bib11], [@bib12]; [@bib63]). As whole Dystrophin structure has not been reported, one can imagine that a compact rapidly diffusing Dystrophin conformation may account for Dystrophin dynamics in vivo. For now, it is not known whether cytoplasmic Dystrophin also exists in low amounts in adult human skeletal muscle cells. However, many studies have shown that, in human embryos and foetuses, Dystrophin first appears in the cytoplasm ([@bib65]; [@bib18]; [@bib16]; [@bib47]; [@bib59]). Interestingly, a cytoplasmic Dystrophin pool was also found in the adult heart ([@bib50]) and in both regenerating fibres ([@bib32]) and differentiating human primary muscle cultures ([@bib45]), where Dystrophin localisation was suggested to recapitulate the embryonic process of Dystrophin deposition, accumulating initially in the cytoplasm and muscle--tendon junctions at the fibre ends, prior to maturing towards costameric localisation. Therefore, it would be particularly interesting to analyse Dystrophin dynamics in the cytoplasm of human dystrophic muscle cells, which undergo repeated cycles of regeneration.

Immobile- and mobile-bound Dystrophin {#s3-3}
-------------------------------------

Our direct semi-quantitative FRAP analysis of bleaching and recovery allowed identification of two populations of immobile- and mobile-bound Dystrophin. The dynamic mobile-bound pool is found in fibres with undetectably low levels of cytoplasmic huDysGFP, zfDysGFP, or endogenously-driven zfDysCitrine, indicating that the mobile-bound state occurs independently of over-expression or high level cytoplasmic accumulation.

A proportion of the Dystrophin located at muscle fibre tips is in free exchange with the cytoplasmic diffusible pool, whereas a further portion binds stably at muscle fibre tips. Whether this immobile pool is generated by stabilisation of the mobile-bound pool, or by another route, remains to be determined ([Figure 11](#fig11){ref-type="fig"}). It is not clear whether the dynamics of early tip-localised Dystrophin is different from the later costameric Dystrophin. The tip region of zebrafish muscle fibres corresponds to myotendinous junction at the ends of human muscle fibres, where Dystrophin is also found enriched in humans ([@bib69]) and in several other mammals, namely mouse ([@bib56]), rat ([@bib32]), and guinea pig ([@bib44]).

The immobile Dystrophin pool at the cell tips is bound tightly enough to transmit significant (10 pN/molecule) forces for significant (1 s) times, enough to unfold Dystrophin\'s spectrin domains ([@bib8]). Dystrophin in the bound mobile pool presumably cannot transmit significant force. However, weak binding would allow response to weak short-lived (sub-pN/molecule, sub-second) forces or may fulfil another function, such as structure assembly, sensing, or signalling. Interestingly, studies of mutants of ezrin, which, like Dystrophin, binds both β-dystroglycan and actin, revealed immobile and mobile membrane bound forms ([@bib20]; [@bib57]). The dynamic membrane-bound ezrin was suggested to be an intermediate conformation state leading to actin anchoring and full complex assembly. Similarly, it is possible that Dystrophin binding to β-dystroglycan facilitates a conformation change to promote actin binding and stabilization of the complex ([@bib24]) ([Figure 11](#fig11){ref-type="fig"}). Membrane localization, turnover, and clustering of other adhesion molecules such as cadherins is known to be influenced by the tension experienced by the cells ([@bib22]; [@bib68]; [@bib21]). Thus, it would be interesting to investigate whether muscle contraction might favour the conversion of some of the mobile-bound or cytoplasmic Dystrophin into immobile Dystrophin.

mRNA accumulation at the tip of muscle cells {#s3-4}
--------------------------------------------

Our expression vectors contain a CMV promoter that drives human and zebrafish Dystrophin expression throughout the fish. Nonetheless, we observed that muscle cells accumulate Dystrophin protein much more frequently than other cell types, suggesting that human Dystrophin stabilization is tissue dependent. The availability of suitable docking sites or specific partner proteins may play a role in stabilization ([@bib42]). In addition, sub-cellular accumulation of the mRNA itself may contribute to Dystrophin positioning at the tip. Like zebrafish Dystrophin mRNA, RNA encoding human Dystrophin localized near the tips of fibres. The expression constructs engineered in the present study do not contain the Dystrophin 5′- or 3′-UTR or introns. Instead, the coding sequence is preceded by a standard chimaeric intron. While previous studies showed a role for 5′ and 3′ UTR regions into controlling tissue-specific expression and transcriptional regulation of Dystrophin (see [@bib41] and references therein), our results show that UTR regions are dispensable for accumulation of the mRNA at the tip. It is therefore unlikely that Dystrophin RNA accumulation at the tips is due to specific RNA transport since that would most likely require the presence of the untranslated regions (for review see [@bib36]; [@bib28]). Thus, the signals controlling the correct localization of the mRNA remain unclear. One possibility is anchorage by numerous nascent protein chains ([Figure 11](#fig11){ref-type="fig"}). This might then facilitate transition of Dystrophin into the strongly bound form.

Transferring the present model to general studies on protein dynamics {#s3-5}
---------------------------------------------------------------------

The new analysis methods developed here broaden the applications of FRAP. Specifically, our modelling overcomes low signal-to-noise ratios and accounts for diffusion during intentional bleaching and unintentional bleaching during imaging. Bleaching due to imaging is here used to analyse binding dynamics. Indeed, at the high laser powers needed in vivo a specific bleaching step may not be necessary, or even optimal. These advances may be generally valuable for studies of embryos and thick tissues or biomaterials by allowing higher laser powers. Also, our results show that pooling results from different cells in a complex in vivo environment may lead to error and mask individual cell-to-cell variability. Finally, our model for one-dimensional diffusion may be especially useful in elongated cells such as muscle cells or neurons. The model was implemented in open-source software that fits diffusion coefficients to data without programming ('Materials and methods'). Our methodology may have general application for analysis of protein dynamics in vivo.

In conclusion, the present study reveals for the first time the complex dynamics of Dystrophin in maturing muscle cells within the intact animal. It reveals important cell-to-cell variations that most likely reflect fibre or tip maturation but could have another origin. Both developmental state and genetic background are thus expected to influence the stability of Dystrophin, which could prove important in the clinic. Unstable binding or overall shortage of a specific pool may affect Dystrophin turnover and muscle performance. In future, the methodology developed here can be used to test for the comparative performance of short Dystrophin forms in use in gene therapy trials, with the aim of focusing on stable versions that may favour a more successful clinical outcome.

Materials and methods {#s4}
=====================

Expression plasmids {#s4-1}
-------------------

Full-length 427-kd human Dystrophin (huDys) was produced by generating a human Dystrophin cDNA using long-range PCR (primers F1: SpeI_GACTAGTGTGTTCTTCATATGTATATCCTTCC; R1: MluI_CGACGCGTCATTGTGTCCTCTCTCATTG), digested with SpeI and MluI and cloned into pCI plasmid (Promega, Madison, WI, United States) downstream of a CMV promoter at the NheI and MluI restriction sites. Insertion of GFP tag: (1) primers F2 (TCACCTCGAGAAAGTCAAGGCACTTCGAGGAGAAATTG, matching the 3′ huDystrophin cDNA plus a 5′ XhoI site) and R2 (CCTCGCCCTTGCTCACCATGGTTGTGGCCATTGTGTCCTCTCTCATTGGCTTTCCAGGGGTATTTCTTC, designed to remove the Dystrophin stop codon and harbouring first 30 nucleotides of eGFP cDNA) were used on huDys; (2) eGFP cDNA was amplified with F3 (GAAGAAATACCCCTGGAAAGCCAATGAGAGAGGACACAATGGCCACAACCATGGTGAGCAAGGGCGAGG, containing a 5′ free tail encoding the Dystrophin cDNA end) and R3 (GGTACCACGCGTTTACTTGTACAGCTCGTCCATGCC, plus a MluI site); (3) finally, the two products were mixed, amplified with F2 and R3, digested with XhoI and MluI and inserted into pre-digested huDys to generate huDysGFP. GFP was expressed from pCMV-GFP (Addgene 11153). Full-length zebrafish Dystrophin ([@bib40]) GFP tagged was synthesized by GenBrick and subcloned into pCI-Neo at the MluI-SalI site (GenScript USA Inc., Piscataway Township, NJ, United States). All constructs were fully sequenced.

Animals, injections, heat shock and embedding {#s4-2}
---------------------------------------------

Fish used were King\'s wild-type *Danio rerio*, *dmd*^*ta222a/+*^, *Tg(actc1b:mCherry)*^*pc4*^ ([@bib19]), and *Gt(dmd-Citrine)*^*ct90a*^ ([@bib60]; [@bib52]) and were staged and reared as described ([@bib66]). Plasmids were injected into 1-cell stage embryos at 20--40 pg/embryo. Phenolthiourea (0.003%) was added to inhibit pigmentation. Heat shock was performed at 6 s and embryos analysed at 48 hpf ([@bib52]). To image, 48 hpf dechorionated embryos were anaesthetized with tricaine (0.2 mg/ml) and embedded in 1.5% low melting point agarose diluted in fish water.

Immunohistochemistry and in situ hybridization {#s4-3}
----------------------------------------------

Standard protocols were used. Embryos were fixed in cold methanol for Dystrophin staining, or otherwise in paraformaldehyde 4%. Antibodies were mouse anti-Dystrophin MANDRA1 (1:100; Novocastra, Roche, Basel, Switzerland), mouse anti-human Dystrophin Dy8 (1:100; Novocastra, Roche), rabbit anti-GFP (1:500; Roche), goat anti-mouse Alexa-543, and goat anti-rabbit Alexa-488. NMJ were detected with conjugated bungarotoxin-594 (1:1000, Invitrogen, ThermoFisher Scientific, Waltham, MA, United States). In situ hybridization was performed as previously described ([@bib27]), with a specific probe against human Dystrophin spectrin repeats 20--22.

Microscopy and analysis software {#s4-4}
--------------------------------

An upright Zeiss Exciter laser scanning microscope (LSM) with a 40×/1.1 W Corr LD C-Apochromat objective, and an inverted Zeiss 710 LSM with a 20×/1.0 W Plan-Apochromat and a 40×/1.3 Plan-Apochromat objective were used for FRAP and *Z*-stacks. Acquisition and maximum intensity projections were made with ZEN 2009/2010 (Zeiss, Jena, Germany). Volocity version 6.0.1 (PerkinElmer, Waltham, MA, United States) was used for *XYZ* projection, to which a fine Gaussian filter was applied and brightness corrected for visualization purposes only. Images were uniformly contrasted with Adobe Photoshop CS4. Illustrations were made in Adobe Illustrator CS3. GraphPad Prism 6 was used for statistical analysis and graph plotting.

Integrated density analysis {#s4-5}
---------------------------

This parameter is a measure of the amount of fluorescence signal resulting from the expression of huDysGFP in a cell or defined sub-cellular region. Confocal Z-stacks of muscle fibres were acquired as 8-bit greyscale images with a voxel size of 0.147 µm × 0.147 µm × 1 µm (x,y,z). ImageJ v1.45a was used for the next steps. The fibre tips or cytoplasm regions were manually delimited on sum projections of the pixel intensities over z-stacks. The raw integrated density (sum of the values of the pixels) in the tips and cytoplasm areas was measured and corrected for the average background. An approximate best correction for the contribution of cytoplasm signal at the tip region, typically at up a 45° angle to the field of view, was made by subtracting the corresponding cytoplasmic signal to half the tip area.

FRAP parameters {#s4-6}
---------------

Bleaching was performed at 100% intensity of an argon laser at 488 nm for GFP and 514 nm for Citrine. The acquisition region was a 300 × 60 pixel rectangle (44 µm × 8.8 µm), the interval between scanning rounds 0.2 s at a pixel dwell of 1.6 µs. For cytoplasmic studies, an open pinhole was used to optimize capture of the dim Dystrophin cytoplasmic signal, whereas a 1 Airy pinhole was generally used for GFP (except cells 6 and 7, [Table 1](#tbl1){ref-type="table"}). For studying the tips, the pinhole was set at 1 Airy to improve imaging resolution of the tip region and bleaching was performed on a 60 × 20 pixels rectangle with a single scan at pixel dwell of 12.8 µs, thus minimizing bleaching time. Conditions for zfDysCitrine FRAP were adapted to avoid depleting too much of the very low cytoplasmic pool. Also see [Figures 4, 6A](#fig4 fig6){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}.

Modelling cytoplasmic FRAP experiments {#s4-7}
--------------------------------------

The model considers diffusion in one dimension, *X*, of a single species in a spatially uniform background and includes bleaching by each imaging scan. The differential equation for the concentration of fluorescent protein *C*~*f*~(*X*, *t*) is$$\frac{\partial C_{f}\left( \left. {X,t} \right) \right.}{\partial t} = D\frac{\partial^{2}C_{f}\left( \left. {X,t} \right) \right.}{\partial X^{2}} - \beta\text{Θ}_{FV}\left( X \right)\left( \left. {\sum\limits_{i}\delta\left( t_{i} \right)C_{f}\left( {X,t} \right)} \right) \right.,$$where *D* is the diffusion constant. The first two terms are the normal diffusion partial differential equation. The third term accounts for bleaching at each image acquisition. For each acquired image a fraction *β* of the fluorescent protein in the imaged area is assumed bleached. The sum is over the image acquisition times *t*~i~. The indicator function Θ~*FV*~*(X)* is one within the scanned field of view and zero outside of it. The delta function at time *t*~i~ of the acquisition of the *i*\'th image (*δ(t*~*i*~*)*), assumes that bleaching occurs in the entire imaged region instantaneously. The fitting procedure is a least-squares two-parameter fit, *D* and β, to the FRAP curve. The boundary conditions for this equation are that the first image after bleaching is given by a Gaussian fit to the profile in this first image, and zero-flux boundary conditions at the two tips of the model cell. The equation is solved within a box approximately as long as the cell and much larger than the imaged region. The entire cell is modelled as the protein diffuses in and out of the imaged region. The effect of varying cell length and position of the bleached region in the model was quantified and deemed minimal ([Table 1](#tbl1){ref-type="table"}).

To compare the experimental data with the model results, background subtracted pixel values are averaged along the *Y*~*T*~-axis to obtain profiles of intensity as a function of *X*~*T*~*.* Background is defined as the average intensity signal from a rectangular region outside the cell over pre-bleach images 4--20. A normalized profile for the first post-bleach point is constructed by dividing the first post-bleach profile by the average of the profiles in pre-bleach time points 4--20*.* A Gaussian *A*~*0*~ − *C*~*0*~*exp*\[*−*(*X* − *X*~*0*~)^*2*^*/*(*2σ*^*2*^)\] is fit to this normalized post-bleach profile, providing an initial profile for the FRAP-curve simulation. The parameters of the profile at the end of bleaching, *A*~*0*~, *C*~*0*~, *X*~*0*~, and *σ* are, respectively, the normalized intensity far from the region bleached, the maximum bleaching depth, the centre of the bleached region (along the *X*-axis), and the bleaching width. *A*~*0*~ is set to *A*~*0*~ = *1*, the remaining three parameters are fit.

The normalized FRAP curve experimental points are compared with the average value in the computed profile in the bleached region. Fitting is done by minimizing the sum-of-the-squares of the difference between the two, to obtain the best-fit values of *D* and *β*. For fits to the initial recovery only, bleaching is small and so a one-parameter fit to *D* is done in this case.

Analysis of fibre tip FRAP data {#s4-8}
-------------------------------

Fibre tips are divided into two 60 × 20 pixels areas, each covering approximately half of a typical tip, together with some cytoplasm and some pixels outside the cell. ([Figure 6A](#fig6){ref-type="fig"}). One box is intentionally bleached (bleached tip), while the other is imaged in an identical way but not intentionally bleached (unbleached tip). A region of similar size in the cytoplasm at a distance from the bright tip region is also analysed. For all regions, the background is subtracted and time points 4 to 20 are used to generate an initial pre-bleach average image for normalization, as for the cytoplasmic studies described above. The background-subtracted intensity is assumed to be proportional to Dystrophin concentration. To understand Dystrophin dynamics at the tip, and to distinguish between different bound populations, direct semi-quantitative analysis of bleaching and recovery is used. FRAP data are analysed in three ways:Direct analysis of the FRAP curve for the bleached half of the tip. Lack of recovery is strong evidence of immobility on the timescale of the experiment. Rapid, but partial, recovery, are indicative signatures of a mobile pool and an immobile pool.Comparative analysis of unnormalized intensities in the unbleached tip region and cytoplasm. Photobleaching due to imaging lowers the final intensity; this effect and a small immobile pool may be indistinguishable. To counter this problem, the identical photobleaching-due-to-imaging received by the unbleached tip region and cytoplasm is used to probe the dynamics. Unnormalized intensity plots (background-subtracted) allow direct comparison of the amount that is unintentionally bleached and then recovers in the tip and the cytoplasm. Presumably, the size of the cytoplasmic component in a tip pixel is at most equal to that in a cytoplasmic pixel, and its FRAP dynamics are similar. Therefore, a permanent drop in tip intensity that is much larger than the drop in the cytoplasmic intensity indicates a large immobile pool. In addition, a dip for the tip signal that is much larger than that in the cytoplasm, and that rapidly recovers, indicates that there is a dynamic bound pool at that tip. Analysis of unnormalized minus cytoplasm intensity curves evaluates if at least 50% of the final recovery occurred at the first or second time points after switching from fast to slow (every 10 s) acquisition rates.Analysis of the difference between bleached and unbleached tip regions. Both regions of the tip receive the same bleaching-due-to-imaging for ∼250 s. If the final difference is large, presumably there is a bound population with a bound lifetime of at least hundreds of seconds. However, if the difference is close to zero, then any bound species is dynamic on this timescale.

Whole cell bleaching and evaluation of recovery fraction due to dark state {#s4-9}
--------------------------------------------------------------------------

Tests were made to evaluate whether bleaching may cause a significant portion of huDysGFP to enter a transient dark state, which then contributes to the fractional recovery after photobleaching. Typically, huDysGFP was bleached in an entire muscle fibre in vivo. Cells expressing high levels (including in the cytoplasm) were chosen to allow better detection of potential low levels of a dark-state pool. Bleaching was performed using the Argon laser at 100%, at which intensity we measured a direct laser power of 0.39--0.5 mW. To image the whole cell, a 20×/1.0 W Plan-Apochromat (Zeiss) objective was used. Due to the size of a muscle cell, similar tests bleaching the entire cell are not possible to perform using exactly the same conditions as in our FRAP experiments, where a 40×/0.8 Achroplan (Zeiss) objective was used. However, the laser power per area is higher in the conditions we use both in cytoplasmic and tips FRAP experiments, which is demonstrated by [@bib48] to further decrease the effect of dark state. After whole-cell bleaching very low recovery after photobleaching is detected (\<1%), presumably due to a shift from dark state to excitable huDysGFP.

Software {#s4-10}
--------

A user-friendly application to analyse cytoplasmic diffusion along the long axis of a cell is freely available (see instructions in [@bib70]).

Datasets {#s4-11}
--------

The original datasets and main individual FRAP analysis files are deposited in the Dryad Digital Repository ([@bib70]).
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Major dataset {#s6-1}
-------------

The following dataset was generated:

Bajanca F, Gonzalez-Perez V, Gillespie SJ, Beley C, Garcia LM, Theveneau E, Sear RP, Hughes SM2015,Data from: In vivo dynamics of skeletal muscle Dystrophin in zebrafish embryos revealed by improved FRAP analysis,<https://dx.doi.org/10.5061/dryad.qg8dt>,Available at Dryad Digital Repository under a CC0 Public Domain Dedication.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for choosing to send your work entitled "In vivo dynamics of muscle Dystrophin revealed by improved FRAP analysis" for consideration at *eLife*. Your full submission has been evaluated by Sean Morrison (Senior Editor) and three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the decision was reached after discussions between the reviewers. Based on our discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Although all reviewers concur on the novelty and potential relevance of your work, major concerns were raised on the experiments performed to support your conclusions. In particular the over-expression of human dystrophin in a wt zebrafish, which already produces its own dystrophin, was considered as a potential cause for the cytoplasmic pool. Moreover, the differences between the human and the fish protein may be at the basis of the different membrane bound pools.

Reviewer \#1:

This is a well written and executed work that proposes a novel, exciting and potentially very important new mechanism of dystrophin localisation and dynamics inside the muscle fibre. Given the relevance of the conclusions deriving from this work, it is essential that possible biological artefacts be ruled out. Unfortunately they are not.

The major concern is the fact that a human protein is over-expressed in a remotely distant species. Therefore to validate the conclusions, it would be important to know:

1\) What are the level of expression of total dystrophin (zebrafish + human) in the fish and how many times it exceeds the wt level? A WB analysis of total dystrophin would have clarified the level of overexpression. The cytoplasmic pool may be simply a consequence of the over expression and may not exist in a wt animal. Moreover, in order to conclusively demonstrate that human dystrophin functionally replaces the fish counterparts, experiments should have been performed in dystrophic zebrafish embryos, with the double advantage to be able to modulate the level of expression to wt levels and, equally important, to demonstrate that human dystrophin rescues muscular dystrophy in the fish. The authors mention that human dystrophin rescues muscular dystrophy in the fish only as "unpublished" in the Discussion. While it is understandable that they may want to publish these data separately, the problem of level of expression remains.

2\) Even though human dystrophin localises like its zebrafish counterpart, the spatial organization is significantly different in the embryos of two species as is the overall muscle structure. Moreover, accumulation at the muscle fibre tip is not observed in human muscle and this is a matter of concern to extrapolate that what observed in the zebrafish also occurs in human muscle. To conclusively demonstrate this, the experiments should be repeated in a well-differentiated DMD muscle fibre in vitro, as it is now possible to obtain with biomaterials and stretching. While this would be a completely new work and it would be unfair to ask to include all this work in this paper, the concern on extrapolating these data to human muscle remains and bears consequences on the design of dystrophin replacement strategies in patients.

3\) Although all the proteins interacting with dystrophin are well conserved during vertebrate evolution, there is no evidence in the paper that rules out that the bound mobile dystrophin pool may be the consequence of a weaker interaction of human dystrophin with fish complex proteins and may not exist in human cells, or even in the zebrafish embryo expressing a wt level of the fish protein.

Because of these major biological concerns, publication of the article in its present form is not recommended, since the intriguing and important conclusions of this work are not validated by the data presented.

Reviewer \#2:

The authors propose a novel hypothesis according to which a large fraction of Dystrophin is present in a soluble cytoplasmic form. However, the whole study is based on unsupported and possibly erroneous assumptions that human Dystrophin, fused to GFP tag, and over-expressed in zebrafish myofibres, is functionally and kinetically equivalent to the native protein.

First, it is important to consider that zebrafish and human Dystrophin differ at amino acid level and hence the affinity of the human protein might be lower to its binding partners at the zebrafish sarcolemma. This can lead to the accumulation of the human protein in the zebrafish myofibre cytoplasm. Indeed, the data presented in the manuscript tends to support this, as the authors did not detect any endogenous zebrafish Dystrophin in the cytoplasm. It might be due to undetectable level in the cytoplasm, as the authors hypothesize. However, if this is the case, then it should be proven by cell fractionating and biochemical methods.

Second, all the conclusions rely on using an overexpression plasmid that is controlled by viral promoter. It is probable that there are limited binding sites for Dystrophin at the cell membrane and such overexpression system would lead to the accumulation of protein in the cytosol. In fact, the authors show that at low expression level they could not find Dystrophin-GFP in the cytoplasm. Expression driven by endogenous promoter would have eliminated all these concerns (i.e. BAC transgenic fish).

Third, the authors fail to show whether the C-terminal GFP tag alters Dystrophin kinetics. Although GFP size is small relative to Dystrophin, it is large enough to alter binding affinity to other proteins. While GFP-tagged human Dystrophin can rescue dystrophic zebrafish in short-term experiments, then this do not require native protein kinetics. Control experiments with N-terminal tag would have been essential. Especially considering that the C-terminus of Dystrophin is located towards the membrane bound dystroglycan complex and the addition of GFP could have weakened the interaction of the fusion protein with it.

Fourth, as it appears from the Materials and methods section, the area that was bleached in FRAP was significantly lager in the cytoplasm than at the membrane. Yet, one cannot compare two regions with different size as diffusion occurs faster in a smaller area. By using a small bleached area at the membrane one would overestimate protein diffusion there in comparison to much larger bleached area in the cytoplasm.

In sum, it is possible that Dystrophin can be present in the cytoplasm, but the manuscript fails to provide convincing experimental support for this. Correct analysis of Dystrophin kinetics in zebrafish would require complete restructuring of the work, focusing on the kinetics of the native protein, preferably in its original genomic location. Biochemical and cell biology experiments can be implemented to study Dystrophin in human muscle fibres. In either case this would involve a significant amount of work and this reviewer cannot see a possibility to recommend the current study for publication.

Reviewer \#3:

This manuscript describes a very interesting investigation of the mobility of dystrophin within developing muscles of the zebra fish embryo. Although the functional equivalencies of this protein in the two species are not precisely matched, the visual accessibility provided by the zebra fish system provide a unique opportunity to examine the behaviour of this protein at the molecular level. The general validity of the approach is justified by a comparison of the distribution of the labelled human dystrophin with that of the endogenous zebra fish dystrophin. The investigation of the mobility of labelled dystrophin protein is a heavily modified version of the standard recovery from bleaching technique for measuring protein mobility.

The outcome is the conclusion that there is little lateral diffusion or other movement within the membrane-bound dystrophin compartment, most restoration of dystrophin to sites of bleached membrane occurring by interchange with the much larger cytoplasmic compartment. The other main conclusion is that there are two bound states of dystrophin, a strong slowly exchanging state, presumed to be in strong association with other proteins of the membrane complex and a more rapidly exchanging state the nature of whose binding is uncertain.

Overall, the investigation is interesting, carefully performed, controlled and interpreted. It provides new information that, with due allowance for the differences between the model of developing zebra fish muscle and postnatal human muscle in which it the object of medical interest, usefully enhances our understanding of its functional properties.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for your letter appealing our initial decision. We have consulted among the editors and would be willing to encourage the submission of a revised manuscript, though we cannot guarantee the final outcome.

In your letter you stated two main points that addressed two of three major concerns. However we believe that you may also have or can easily produce data to address the third and final important concern. Specifically:

1\) You stated clearly (but this was not in the first version) that the cytoplasmic pool might well be an artifact due to over expression. Once this is made clear there is no longer the risk to mislead the reader about a physiologically significant pool of soluble dystrophin.

2\) You proposed to insert the rescue of the dystrophic fish by human dystrophin. A careful analysis of the resulting phenotype would strengthen the work considerably.

3\) The third concern that you do not address in your letter relates to possible different binding kinetics between fish and human proteins. This is important because the labile membrane bound pool may be a consequence of this difference. If you have performed, as control, rescue of dystrophic fish by fish dystrophin and you also see the two pools, that would be sufficient to rule out a species difference. Ideally one would like to see the same also in human cells but we understand that this would be a whole new set of experiments that you may not be in a position to do. If the fish data can be provided, then just a word of caution in the discussion, as to the fact the final confirmation of the two pools in human muscle awaits experiments in human cells should acknowledge the unlikely possibility that things may be different in human.

Therefore, if you think you can address the three major points raised we would be happy to reconsider the manuscript.

10.7554/eLife.06541.020

Author response

*\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision*.*\]*

We are pleased to read that the reviewers agree on the novelty and potential relevance of our work, and understand the major concerns that lead to the rejection decision. However, each of the major concerns is based on a wrong assumption that we would like to challenge.

Firstly, it is not true to say that zebrafish Dystrophin is located differently from human Dystrophin and that this gives grounds to worry about the relevance of our work to humans. We present below extensive bibliographic evidence of the similar distribution of human and zebrafish Dystrophins. While, of course, work in a model organism cannot be thoughtlessly applied to humans, it has nevertheless proved highly relevant in many areas of biomedicine. Secondly, it is incorrect to suppose, as Reviewer 2 seems to do, that we regard the observed cytoplasmic pool of Dystrophin as a key feature of our findings. We obviously did not explain clearly enough, for which we apologize. Like Reviewer 2, we think the large cytoplasmic pool present in some fibres is simply an artefact of over-expression. Nevertheless, we showed that the size of the cytoplasmic pool does not determine Dystrophin binding dynamics, and specifically, does not determine our new weakly membrane-bound Dystrophin pool. Thirdly, Reviewers 1 and 2 both thought we needed to demonstrate functional relevance. We now have data showing that human Dystrophin-GFP rescues the fish *dmd* mutant phenotype cell autonomously at a single fibre level. While these new extended functional data were previously intended to form a second manuscript, we would be willing to add them to the present manuscript if a resubmission were allowed.

Please find below a more detailed refutation of the major criticisms by reviewers 1 and 2 that includes new data to support our claims. Reviewer 3 is very positive and does not present any major criticism.

Reviewer \#1:

*1) What are the level of expression of total dystrophin (zebrafish + human) in the fish and how many times it exceeds the wt level? A WB analysis of total dystrophin would have clarified the level of overexpression*.

Thank you for this comment. We have addressed this point. Unfortunately, western blots are not relevant as our expression is intentionally mosaic in single isolated cells to permit FRAP. In addition, note that immunostaining using MANDRA1 antibody, which recognizes a conserved epitope on both human and zebrafish Dystrophins, does not show increased accumulation at the ends of fibres containing huDysGFP compared with adjacent fibres lacking huDysGFP ([Figure 1C](#fig1){ref-type="fig"}). Thus, the presence of excess cytoplasmic huDysGFP likely displaces some of the endogenous Dystrophin, rather than forcing extra binding sites to form. Further, the huDysGFP intensity in the whole fibre and locally at the fibre tips was measured in wild-type embryos (where it coexists with the endogenous Dystrophin) and in *dmd*^*ta222a*^ dystrophic embryos ([Figure 8C](#fig8){ref-type="fig"}). In the absence of competition with the endogenous protein, huDysGFP can occupy all the available binding sites, showing a 2.5 fold increase in the intensity ratio tips:cytoplasm comparing with that found in wild-type background. Or, in different words, fibres expressing the same intensity in the cytoplasm can accumulate more at the fibre ends in the mutant background. This nicely shows that our experiments in the wild type background were made in non-saturating conditions. Moreover, we have repeated the key FRAP experiments in the dystrophic background and our analysis found no differences regarding the cytoplasmic pool or the mobile and immobile bound fractions ([Figure 8](#fig8){ref-type="fig"}; Results section "Human Dystrophin efficiently rescues zebrafish dystrophic embryos and two bound pools are still found in the absence of competition with endogenous Dystrophin").

*The cytoplasmic pool may be simply a consequence of the over expression and may not exist in a wt animal*.

We do agree that most of the cytoplasmic Dystrophin that accumulates in highly expressing fibres is a consequence of the over expression. We now make this point clear both in the Results and Discussion sections. However, the existence of a cytoplasmic pool does not invalidate our results. Firstly, our data rules out that the size of the cytoplasmic pool affects the overall binding (see Results section "Increase of cytoplasmic Dystrophin does not affect accumulation at the fibre tips"). Secondly, the weakly-bound Dystrophin pool can be found in fibres with no detectable or very low levels of cytoplasmic unbound huDysGFP (see [Figure 6B,F](#fig6){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}), and cells with high cytoplasmic huDysGFP intensity do not necessarily recover more (compare [Figure 6C,E,F](#fig6){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). This implicates that the size of the cytoplasmic pool does not determine the weakly-bound Dystrophin pool.

Furthermore, we have now added the FRAP analysis of endogenously-driven zebrafish Dystrophin ([Figure 10](#fig10){ref-type="fig"}; Results section "Endogenous zebrafish Dystrophin diffusion and binding dynamics"). Our results show clearly that there are low levels of endogenous cytoplasmic Dystrophin in muscle fibres of *Gt(dmd-citrine)*^*ct90a*^ zebrafish embryos, in which the endogenous gene was tagged by a gene trap. We demonstrate that endogenous zebrafish Dystrophin also shows the characteristic two bound pools at the membrane.

Importantly, note that the observed accumulation in the cytoplasm mimics the expression pattern observed in embryonic/foetal human muscle fibres. Wessels and colleagues showed that in human embryos Dystrophin first appears in the *cytoplasm*, at the *ends of myotubes* (see [Figure 3e](#fig3){ref-type="fig"} in [@bib65], ). It then becomes widespread throughout the myofibres in foetal stages (see [Figure 4d](#fig4){ref-type="fig"} in [@bib65]), becoming restricted to the sarcolemma only in maturing and adult muscles. Several other studies from different labs and using a wide range of different antibodies (including some of the most extensively used nowadays like DYS-1, DYS-2, DYS-3) confirm the initial cytoplasmic accumulation in human embryos and that the level of internal staining declines with age and is considerably lower in adult muscle ([@bib18]; see [Figure 3](#fig3){ref-type="fig"} in [@bib16]; [@bib47]; [@bib59]). Interestingly, a cytoplasmic Dystrophin pool was also found in regenerating muscle fibres (e.g., Kääriäinen et al., Neuromuscul Disord. 2000), in differencing human primary muscle cultures (e.g., Miranda et al., Am J Pathol. 1988) and in the adult heart (e.g, Peri et al., Mol Cell Biochem. 1994). Therefore, even though there are cases in our study where large amounts of Dystrophin accumulate in the cytoplasm due to overexpression, it is very likely that baseline biological levels are present in most cells, at least in the embryonic context that we study here.

*Moreover, in order to conclusively demonstrate that human dystrophin functionally replaces the fish counterparts, experiments should have been performed in dystrophic zebrafish embryos, with the double advantage to be able to modulate the level of expression to wt levels and, equally important, to demonstrate that human dystrophin rescues muscular dystrophy in the fish. The authors mention that human dystrophin rescues muscular dystrophy in the fish only as "unpublished" in the Discussion. While it is understandable that they may want to publish these data separately, the problem of level of expression remains*.

Thank you for pointing this out. We are happy to include the analysis of human Dystrophin expression in dystrophic fish (*dmd*^*ta222a/ta222a*^). We show that exogenous human Dystrophin efficiently rescues the dystrophic phenotype indicating that human Dystrophin is fully functional within fish muscle cells and analyse Dystrophin binding dynamics in rescued DMD fibres by FRAP ([Figure 8](#fig8){ref-type="fig"}; Results section "Human Dystrophin efficiently rescues zebrafish dystrophic embryos and two bound pools are still found in the absence of competition with endogenous Dystrophin"). We find no differences between the dynamics of huDysGFP in wild type embryos and in DMD embryos. This result indicates that the competition with endogenous zebrafish Dystrophin in the original wild-type host embryos was not the cause of the mobile-bound Dystrophin pool we observed.

*2) Even though human dystrophin localises like its zebrafish counterpart, the spatial organization is significantly different in the embryos of two species as is the overall muscle structure. Moreover, accumulation at the muscle fibre tip is not observed in human muscle and this is a matter of concern to extrapolate that what observed in the zebrafish also occurs in human muscle. To conclusively demonstrate this, the experiments should be repeated in a well-differentiated DMD muscle fibre in vitro, as it is now possible to obtain with biomaterials and stretching. While this would be a completely new work and it would be unfair to ask to include all this work in this paper, the concern on extrapolating these data to human muscle remains and bears consequences on the design of dystrophin replacement strategies in patients*.

This is indeed a very interesting point. However, we respectfully disagree with the reviewer argument that there are key differences between our observations and the reality of Dystrophin localisation in human muscles that render our data on human Dystrophin in fish cells irrelevant. In the original submission, it was our mistake not to properly highlight the similarity between human and zebrafish Dystrophin localisations, when both cell location and developmental stage are taken into account. Human Dystrophin localises in zebrafish embryonic muscles just as it localises in human embryonic muscles. As already mentioned above, several studies showed that in human embryos and foetuses Dystrophin first appears in the *cytoplasm*, at the ends of myotubes and then widespread, before becoming restricted to the sarcolemma (see [Figure 3e](#fig3){ref-type="fig"} in [@bib65]; [@bib18]; see [Figure 3](#fig3){ref-type="fig"} in [@bib16]; [@bib47]; [@bib59]). In the original study, [@bib65] said that "The sarcoplasmic localization in embryonic and fetal tissue and the sarcolemmal localization of dystrophin in mature muscle *suggests the accumulation of dystrophin in the cytoplasm prior to its integration into the membrane*." The same group also detected cytoplasmic accumulation in an aborted Duchenne foetus, with antibodies against N-terminal Dystrophin (Ginjaar et al., 1989). While at the time they did not have the tools available to test their hypothesis, our results confirm the existence of a cytoplasmic pool of dystrophin in embryonic muscle cells. It would be nice to be able to analyse this cytoplasmic pool directly in human muscle cells. We now mention this point in the Discussion. We believe it is advantageous to analyse Dystrophin dynamics in developing muscle fibres in the embryo, where binding complexes are actively forming. In the adult, there are presumably more stable complexes with a slower turnover and the discrete details of the assembly mechanism may become harder to spot. However, in human DMD therapy situations the complexes will be forming de novo in existing and nascent regenerating fibres.

Regarding regenerating fibres, relevant in the DMD context, it was shown that the localisation of Dystrophin *recapitulates that found during embryonic muscle development* during regeneration of rat muscles in vivo ([@bib32]) and again in differentiation of human primary muscle cultures ([@bib45]; [@bib59]). In both cases Dystrophin starts by localising in the cytoplasm before incorporating the membrane complexes. Moreover, Dystrophin *was found enriched at the at the myotendinous junction (MTJ) localised at the fibre tip region in human muscle biopsies* (see [Figure 6](#fig6){ref-type="fig"} in [@bib69]; Note the antibodies used are still among the most widely used to these days) and in *several other mammals*, namely mouse (see [Figure 5](#fig5){ref-type="fig"} in [@bib56]), rat ([@bib32]), and guinea pig (see [Figure 7](#fig7){ref-type="fig"} in [@bib44] ). The fact that most studies focus on the costameres expression (which is commonly all that can be observed in a biopsy as surgeons do not perform biopsies near tendons) may in fact contribute to an incomplete view of the biology of Dystrophin in human cells. However, we would like to stress that as our data stands, we do not make direct extrapolations to the human muscle or DMD patients, but the working model arising from our data raises new questions and opens a new avenue for more applied research to follow. We added a statement to the Discussion acknowledging the importance of confirming the dynamics of human Dystrophin in human cells in future studies. We also integrate better the literature on dystrophin in human cells to make it clearer that what we observe in our experimental system fits with previous studies in embryonic and regenerating human muscles (Introduction and Discussion sections).

*3) Although all the proteins interacting with dystrophin are well conserved during vertebrate evolution, there is no evidence in the paper that rules out that the bound mobile dystrophin pool may be the consequence of a weaker interaction of human dystrophin with fish complex proteins and may not exist in human cells, or even in the zebrafish embryo expressing a wt level of the fish protein*.

We completely agree with this comment and have addressed it in two ways. First, we made a new expression construct to exogenously express GFP-tagged zebrafish Dystrophin. This construct was expressed in both wild-type and dystrophic embryos and the binding dynamics were analysed ([Figure 9](#fig9){ref-type="fig"}; Results section "Two bound populations also characterize the dynamics of zebrafish Dystrophin-GFP"). The two bound pools are present in both genetic backgrounds, confirming that the mobile-bound pool is not a consequence of a different binding kinetics between human and zebrafish proteins. However, there was still the possibility that the mobile-bound pool was due to the over-expression strategy. Therefore, our second approach was to perform FRAP analysis of endogenously-driven zebrafish Dystrophin As mentioned in the reply to point 1, this mobile-bound form is also found in muscle fibres of *Gt(dmd-citrine)*^*ct90a*^ zebrafish embryos ([Figure 10](#fig10){ref-type="fig"}; Results section "Endogenous zebrafish Dystrophin diffusion and binding dynamics"). We believe that these new experiments, together with the clear acknowledgment of the importance of confirming the dynamics of human Dystrophin in human cells in future studies that we now add to the Discussion bring our manuscript closer to the expectations of the reviewer.

Considering this is the first study of Dystrophin dynamics in vivo we cannot know if Dystrophin behaves similarly in all species and all developmental stages, but the question is raised. The FRAP analysis developed for this work can now be used to analyse human Dystrophin dynamics in primary muscle cell cultures, or even pluripotent human stem cells differentiated into muscle fibres. However, to perform these experiments in human cells is no trivial task. It will be necessary to transfect the full-length human Dystrophin, or to modify the endogenous *dmd* locus to insert a fluorescent tag, and then to study well-differentiated muscle fibres in vitro, for example by using biomaterials and stretching techniques as suggested by this reviewer. Ideally, 3D cultures with muscle-tendon attachments and innervations would guarantee more reliable results. We believe this first study of Dystrophin dynamics on the zebrafish embryo shows thought-provoking results and sets up a methodology that may now be used to explore further the implications of the proposed model.

Taking into consideration this evidence, we believe that we now provide the main technical controls asked by the reviewer. Importantly, we also better integrate the literature on dystrophin in human cells to make it clearer that what we observe in our experimental system fits with the proposed dynamics of dystrophin in embryonic and regenerating human muscles.

Reviewer \#2:

*The authors propose a novel hypothesis according to which a large fraction of Dystrophin is present in a soluble cytoplasmic form*.

Thank you for this comment, which highlighted the fact that we had been unclear in our original submission. We do not regard the observed cytoplasmic pool of Dystrophin as a key feature of our findings. We think the large cytoplasmic pool present in some fibres is simply an artefact of over-expression. This is now made clear both in the Results and Discussion sections. Yet, since this large cytoplasmic pool is present we had to take it into account in the analysis. We show that this pool exist in a smaller scale in the endogenous situation (citrine fish, please see below) and that the two membrane form of dystrophin are still detectable regardless of the amount of cytoplasmic dystrophin present in the cells. We made several changes in the manuscript to make this point clear. We hope this reviewer will find it satisfactory.

*However, the whole study is based on unsupported and possibly erroneous assumptions that human Dystrophin, fused to GFP tag, and over-expressed in zebrafish myofibres, is functionally and kinetically equivalent to the native protein*.

These are fair concerns. We have now added several controls to better consolidate our results on the human Dystrophin. Importantly, we added data showing that human Dystrophin fully rescues the dystrophic phenotype ([Figure 8](#fig8){ref-type="fig"}; Results section "Human Dystrophin efficiently rescues zebrafish dystrophic embryos and two bound pools are still found in the absence of competition with endogenous Dystrophin") indicating that huDys-GFP is functional in the fish background. In addition, we have analysed the dynamics of exogenous zebrafish Dystrophin with C-terminal GFP-tag, equivalent to the human Dystrophin-GFP, and compared both with endogenous Dystrophin of *Gt(dmd-citrine)*^*ct90a*^ zebrafish embryos, in which a Citrine-tag was inserted close to the actin binding site by a gene trap. We have found similar dynamics in all three conditions, despite the different tags and their different localisation within the protein. Further, our results show that exogenous zebrafish and human Dystrophin have diffusion and binding dynamics similar to those of endogenous zebrafish Dystrophin, in spite of the artificially raised cytoplasmic levels caused by over-expression. Therefore, neither the over-expression nor different binding kinetics between fish and human proteins affect Dystrophin dynamics in our system. In addition to the data added to the Results section ("Two bound populations also characterize the dynamics of zebrafish Dystrophin-GFP" and "Endogenous zebrafish Dystrophin diffusion and binding dynamics"; [Figures 9, 10](#fig9 fig10){ref-type="fig"}), we have improved the Discussion to make clear that our system can be used to study human Dystrophin dynamics, with limitations (see "Validating Dystrophin over-expression in Zebrafish as a model system to study Dystrophin dynamics in vivo"). There, we stress the importance of confirming the dynamics of human Dystrophin in human cells in future studies.

Given that no similar analysis has ever been done on human protein in human (or any other species), our data does, at the very least, raise a valid issue.

*First, it is important to consider that zebrafish and human Dystrophin differ at amino acid level and hence the affinity of the human protein might be lower to its binding partners at the zebrafish sarcolemma. This can lead to the accumulation of the human protein in the zebrafish myofibre cytoplasm. Indeed, the data presented in the manuscript tends to support this, as the authors did not detect any endogenous zebrafish Dystrophin in the cytoplasm. It might be due to undetectable level in the cytoplasm, as the authors hypothesize. However, if this is the case, then it should be proven by cell fractionating and biochemical methods*.

The accumulation of Dystrophin in the cytoplasm does not invalidate our results, independently of any speculation about its driving source. Note that we thoroughly analysed the cytoplasmic pool to make sure its dynamics would be taken into account at all steps of the analysis. We have found that the overall binding of human Dystrophin at the membrane is not affected by the amount of Dystrophin in the cytoplasm (see Results section "Increase of cytoplasmic Dystrophin does not affect accumulation at the fibre tips"). In addition, the size of the cytoplasmic pool does not determine the presence of the mobile-bound Dystrophin pool. Indeed, our data show that the mobile-bound Dystrophin pool can be found in fibres with no detectable or very low levels of cytoplasmic unbound huDysGFP ([Figure 6B, F](#fig6){ref-type="fig"}), and cells with high cytoplasmic huDysGFP intensity do not necessarily recover more (compare [Figure 6C, E, F](#fig6){ref-type="fig"}).

Importantly, we have now added the FRAP analysis of endogenously-driven zebrafish Dystrophin ([Figure 10](#fig10){ref-type="fig"}; Results section "Endogenous zebrafish Dystrophin diffusion and binding dynamics"). Our results show that there are low levels of endogenous cytoplasmic Dystrophin in muscle fibres of *Gt(dmd-citrine)*^*ct90a*^ zebrafish embryos and we demonstrate that endogenous zebrafish Dystrophin also shows the characteristic two bound pools at the membrane. This observation is in line with previous observations. Cytoplasmic dystrophin was shown in developing human muscle fibres independently by different labs, using several different antibodies, many of which are still among the most widely used and more trusted ones (see [Figure 3 and 4](#fig3 fig4){ref-type="fig"} in [@bib65] [@bib18]; see [Figure 3](#fig3){ref-type="fig"} in [@bib16]; [@bib47]; [@bib59]). Cytoplasmic Dystrophin was also described in regenerating muscle fibres ([@bib32]), in differencing human primary muscle cultures ([@bib45]; [@bib59]) and in the adult heart ([@bib50]). Considering that we express the human Dystrophin in a skeletal muscle embryonic environment it is not surprising, and it is even reassuring, that it would behave as in the human embryonic environment and be found in a cytoplasmic form. We apologize that the bibliographic evidence required to put many of our results in context was missing, which, together with the focus on comparing the exogenous human Dystrophin expression with that of the endogenous zebrafish Dystrophin may have misled the reviewer in many ways. We hope these points were now made clearer (Introduction and Discussion).

*Second, all the conclusions rely on using an overexpression plasmid that is controlled by viral promoter. It is probable that there are limited binding sites for Dystrophin at the cell membrane and such overexpression system would lead to the accumulation of protein in the cytosol. In fact, the authors show that at low expression level they could not find Dystrophin-GFP in the cytoplasm. Expression driven by endogenous promoter would have eliminated all these concerns (i.e. BAC transgenic fish)*.

We agree with the reviewer. The new analysis of endogenously-driven Dystrophine-Citrine eliminated these concerns.

*Third, the authors fail to show whether the C-terminal GFP tag alters Dystrophin kinetics. Although GFP size is small relative to Dystrophin, it is large enough to alter binding affinity to other proteins. While GFP-tagged human Dystrophin can rescue dystrophic zebrafish in short-term experiments, then this do not require native protein kinetics. Control experiments with N-terminal tag would have been essential. Especially considering that the C-terminus of Dystrophin is located towards the membrane bound dystroglycan complex and the addition of GFP could have weakened the interaction of the fusion protein with it*.

This is a fair point. We have compared the dynamics of zebrafish Dystrophin with a C-terminal GFP tag with that of zebrafish Dystrophin with Citrine tag localised close to the actin binding site ([@bib52]). We found that Dystrophin dynamics is not affected by the position of the fluorescent suggesting that the tags are unlikely to significantly perturb the dynamics of Dystrophin.

In addition, note that we do show in the manuscript that human Dystrophin without the tag binds like huDysGFP ([Figure1](#fig1){ref-type="fig"}). We also present new data to strengthen our technical controls on the functionality of the GFP-tagged human Dystrophin we use ([Figure 8](#fig8){ref-type="fig"}; Results section "Human Dystrophin efficiently rescues zebrafish dystrophic embryos and two bound pools are still found in the absence of competition with endogenous Dystrophin"). Hence, we believe that the risk of the GFP-terminal tag affecting the binding of Dystrophin is most likely negligible.

*Fourth, as it appears from the Materials and methods section, the area that was bleached in FRAP was significantly lager in the cytoplasm than at the membrane. Yet, one cannot compare two regions with different size as diffusion occurs faster in a smaller area. By using a small bleached area at the membrane one would overestimate protein diffusion there in comparison to much larger bleached area in the cytoplasm*.

We are puzzled by the reviewer's claim that the diffusion rate would be faster in a smaller area. The diffusion rate is a measure of the distance travelled per unit of time (we measure it in micrometers travelled per second). By physical laws, the size of the observed region has no effect on the diffusion rate itself. Therefore, it is absolutely correct to compare different areas/volumes using diffusion equations.

Taking into consideration this evidence, we believe there is no reason to dismiss our results as pure artefacts. The new data presented provides further technical controls that we believe strengthen the manuscript. We acknowledge that a better integration of the literature on Dystrophin in human muscle cells was required to make it clearer that what we observe in our experimental system fits with the proposed dynamics of dystrophin in embryonic and regenerating human muscles.

*\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration*.*\]*

*1) You stated clearly (but this was not in the first version) that the cytoplasmic pool might well be an artifact due to over expression. Once this is made clear there is no longer the risk to mislead the reader about a physiologically significant pool of soluble dystrophin*.

We do agree that there is often an excess of cytoplasmic Dystrophin in the zebrafish host muscle fibres due to over expression. We now make this point clear both in the Results and Discussion sections. The question was raised by the referees with the concern that an excess of cytoplasmic Dystrophin could be the cause of the mobile-bound pool identified. To further support our original claims that the existence of extra cytoplasmic Dystrophin does not invalidate our results, we have now added the FRAP analysis of endogenously-driven zebrafish Dystrophin ([Figure 10](#fig10){ref-type="fig"}; Results section "Endogenous zebrafish Dystrophin diffusion and binding dynamics"). Although this experiment was not requested by the editors, we believe it adds important new data. Our results show clearly that there are low levels of endogenous cytoplasmic Dystrophin in muscle fibres of *Gt(dmd-citrine)*^*ct90a*^ zebrafish embryos, in which the endogenous gene was tagged by a gene trap. We demonstrate that endogenous zebrafish Dystrophin also shows the characteristic two bound pools at the membrane. With these new data in mind, the question is no longer whether there is a physiologically significant pool of soluble Dystrophin, but whether there is a similar low level of soluble Dystrophin in human cells. To put our data into context, we added citation of several independent studies suggesting that this may be the case, at least during development and regeneration. Whether the presence of this cytoplasmic pool is linked with the fact that Dystrophin complexes may be actively being formed in these situations remains an open and interesting question.

*2) You proposed to insert the rescue of the dystrophic fish by human dystrophin. A careful analysis of the resulting phenotype would strengthen the work considerably*.

We have now included the analysis of human Dystrophin expression in dystrophic fish (*dmd*^*ta222a/ta222a*^). We show that exogenous human Dystrophin efficiently rescues the dystrophic phenotype indicating that human Dystrophin is fully functional within fish muscle cells. In addition, we analysed Dystrophin binding dynamics in rescued DMD fibres by FRAP ([Figure 8](#fig8){ref-type="fig"}; Results section "Human Dystrophin efficiently rescues zebrafish dystrophic embryos and two bound pools are still found in the absence of competition with endogenous Dystrophin"). We find no differences whatsoever between the dynamics of huDysGFP in wild type embryos and in DMD embryos. This result indicates that the competition with endogenous zebrafish Dystrophin in the original wild-type host embryos was not the cause of the mobile-bound Dystrophin pool we observed.

*3) The third concern that you do not address in your letter relates to possible different binding kinetics between fish and human proteins. This is important because the labile membrane bound pool may be a consequence of this difference. If you have performed, as control, rescue of dystrophic fish by fish dystrophin and you also see the two pools, that would be sufficient to rule out a species difference. Ideally one would like to see the same also in human cells but we understand that this would be a whole new set of experiments that you may not be in a position to do. If the fish data can be provided, then just a word of caution in the discussion, as to the fact the final confirmation of the two pools in human muscle awaits experiments in human cells should acknowledge the unlikely possibility that things may be different in human*.

We made a new expression construct to exogenously express GFP-tagged zebrafish Dystrophin. This construct was expressed in both wild-type and dystrophic embryos and the binding dynamics were analysed ([Figure 9](#fig9){ref-type="fig"}; Results section "Two bound populations also characterize the dynamics of zebrafish Dystrophin-GFP"). The two bound pools are present in both genetic backgrounds, confirming that the labile-bound pool is not a consequence of a different binding kinetics between human and zebrafish proteins. However, there was still the possibility that the mobile-bound pool was due to the over-expression strategy. As mentioned in the reply to point 1, this mobile-bound form is also found in muscle fibres of *Gt(dmd-citrine)*^*ct90a*^ zebrafish embryos ([Figure 10](#fig10){ref-type="fig"}; Results section "Endogenous zebrafish Dystrophin diffusion and binding dynamics").

We added a statement to the Discussion acknowledging the importance of confirming the dynamics of human Dystrophin in human cells in future studies . Considering this is the first study of Dystrophin dynamics in vivo we cannot know if Dystrophin behaves similarly in all species and all developmental stages, but the question is raised. The FRAP analysis developed for this work can now be used to analyse human Dystrophin dynamics in primary muscle cell cultures, or even pluripotent human stem cells differentiated into muscle fibres. However, to perform these experiments in human cells is no trivial task. It will be necessary to transfect the full-length human Dystrophin, or to modify the endogenous *dmd* locus to insert a fluorescent tag, and then to study well-differentiated muscle fibres in vitro, for example by using biomaterials and stretching techniques. Ideally, 3D cultures with muscle-tendon attachments and innervations would guarantee more reliable results. We believe this first study of Dystrophin dynamics on the zebrafish embryo shows thought-provoking results and sets up a methodology that may now be used to explore further the implications of the proposed model.

[^1]: These authors contributed equally to this work.

[^2]: Diffusion is measured along the *X* (long) axis of the fibre. For most cells, two different size regions were bleached per fibre. The width of the bleached region in pixels is indicated for each data set (one pixel is 0.147 μm wide). Intentional bleaching was performed between time points 20 and 21. Two-parameter, *D* and *β,* fits were performed to long acquisition times, either to time points 21 to 200 (∼40 s) or time points 21 to 500 (∼110 s). One-parameter fits were also performed to only the initial recovery curve (points 21 to 50, or ∼7 s). For the latter fits, bleaching during imaging is too small to fit *β*, so we fix *β* = 0. Results of fits to FRAP curves for GFP and huDysGFP are presented for a model using either the actual fibre length and bleach position or with the standard length of 90 μm and a bleach position at 45 μm. Note that in most GFP cases, the difference between the fitted *D* values for standard and actual lengths and bleach positions is less than 1 μm^2^/s. This is smaller than our estimate of the uncertainties in these *D* values, which is several μm^2^/s. For huDysGFP, there was no difference within two significant figures. Due to the smaller diffusion constants of huDysGFP, varying the cell length within these limits makes no difference to the values of *D*. During a ∼30-s experiment, the bleached profile is not affected by a fibre tip ∼45 μm away, for values of *D* typical of huDysGFP. Values of *D* in the main text are obtained using all *D* values obtained for two-parameter fits to data to point 200, using model cells with the standard cell length and bleach position.

[^3]: Cytoplasm intensity is the background-subtracted intensity on an 8-bit scale. It is calculated in a rectangular region of a few hundred pixels inside the cell but away from the tip and is averaged over images 4 to 20 (the last one before bleaching). Fractional recovery is the ratio *R*~*T*~/*I*~*T*~, where, *R*~*T*~ is the intensity recovery in the tip, and *I*~*T*~ is the average pre-bleach intensity in the bleached region. *R*~*T*~ is the average intensity in the bleached region in the final time point (200), minus that in the first point after bleaching (21), and *I*~*T*~ is averaged over images 4 to 20. Final normalised unbleached minus bleached intensities is the difference between the average normalized intensities in the unbleached and bleached regions, derived from the average of the final 20 time points (181--200). Unbleached minus cytoplasm 50% recovery evaluates if at least 50% of the final recovery of unbleached minus cytoplasm curves was rapidly attained, at the first (\<10 s), second (\<20 s), or later time points after switching from fast to slow acquisition rates. Note that both tips of some fibres were analysed.

[^4]: See [Table 2](#tbl2){ref-type="table"} for detailed information.

[^5]: See [Table 2](#tbl2){ref-type="table"} for detailed information.

[^6]: In embryos subjected to heat shock (tips 1--7), individual fibres could be selected for FRAP, at 48 hpf, and background levels are taken into account, contrary to the remaining cases (tips 8--26). See [Table 2](#tbl2){ref-type="table"} for detailed information.
